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ABSTRACT
Introduction - Outcome after acute injury to the brain depends on the survival of
neurons. This requires an adequate supply of oxygen and metabolites to a cellular
environment which supports cellular metabolic processes. The intracranial and
systemic biochemical changes which occur after injury as a result of activation of
inflammatory cascades may result in both reduced oxygen delivery and altered
cellular metabolism. Therapeutic measures used in the intensive care unit to improve
outcome after brain injury currently include monitoring of cerebral oxygenation and
maintenance of cerebral perfusion by the use of pressor agents. Future management
may include the use of antagonist drugs to biochemical inflammatory mediators, such
as the cytokines or leucocyte adhesion molecules.
Methods - 32 patients admitted to the intensive care unit with either traumatic brain
injury or spontaneous subarachnoid haemorrhage were studied. Paired arterial and
jugular venous sera were taken at time points from admission until 4 days after injury
and concentrations of cytokines, adhesion molecules, and the proteins neuron-specific
enolase (NSE) and S-100 measured. Systemic concentrations and jugular venous-
arterial gradients were studied in relation to each other, neurological outcome at 6
months, and other measures of injury type and severity. A comparison of two
monitors (Critikon 2020 and Invos 3100) used to measure cerebral oxygenation by
means of near infra-red spectroscopy in the intensive care unit was carried out using
volunteer subjects. Assessment of the ability of each monitor to provide stable and
consistent readings in subjects at rest was performed. The effect of controlled arterial
hypertension on cerebral blood flow and metabolism was studied in 32 patients with
acute brain injury in the intensive care unit.
Results - We found significant intracranial production of interleukin-6 after injury,
and raised systemic concentrations of intercellular adhesion molecule-1 (ICAM-1),
NSE and S-100. These systemic changes were all significantly related to outcome.
Concentrations of ICAM-1 were negatively correlated with Glasgow Coma Score,
but were not influenced by the presence of extracranial injuries. Systemic
concentrations of L-selectin were significantly reduced after injury. The Critikon
monitor failed to provide any reading in 44% of subjects, while the Invos failed in
20%. Differences between oxygen saturation readings from each monitor were
related to the average saturation (p<0.001). Cerebral blood flow was adequate in all
patients in the induced hypertension study. 58% of subjects were treated with a
vasopressor to keep cerebral perfusion pressure above 70 mmHg. 33% of subjects
developed cerebral hyperaemia, which was unrelated to vasopressor use.
Discussion - The highly significant relationship between systemic ICAM-1 and
outcome suggests that antagonism of its effects may form part of future drug
therapies for brain injury. The development of new monitoring technologies must
result in monitors which function reliably in the intensive care unit, or their use will
not be considered worthwhile. Induced hypertension is a treatment method which
may reduce the likelihood of cerebral ischemia without resulting in inappropriate
cerebral hyperaemia. Therapeutic measures which monitor and assist in cerebral
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Despite recent advances in the management of patients with acute injury to the
brain, particularly in intensive care, those who have sustained a moderate to severe
injury often have a dismally poor prognosis. Emphasis has previously been placed on
the avoidance of systemic hypotension and hypoxia, but even in intensive care units
where staff adhere rigorously to this approach, outcome appears to have improved
little. A different therapeutic approach may therefore be required.
In the following thesis I shall review and discuss the significance of the
inflammatory process in brain injury, in particular the parts played by the cytokines
and leucocyte adhesion molecules, and the possibility that antagonism of their effects
may form the basis of future drug therapy. This will be followed by a description of a
study which examines the relationships between serial measurements of the cytokines
and adhesion molecules in the serum of patients with brain injury, and relates these to
injury severity and neurological outcome.
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CHAPTER 1
A REVIEW OF THE CYTOKINES AND




The brain, once thought to be relatively shielded from the immunological and
inflammatory processes which occur in the tissues of other body systems after acute
injury, is in fact an active participant in these processes. Injury to the brain, as a result
of trauma, haemorrhage or ischaemia, causes the release of mediators such as the
cytokines, which activate inflammation and cause further secondary brain injury.
Intensive care physicians can do little to alleviate the gravity of the primary injury, but
by understanding the mechanisms responsible for secondary injury, and how these
mechanisms may, in the future, be altered by drug therapy, they may be able to
improve patient management and outcome.
A primary brain injury stimulates the cells of the central nervous system (CNS)
to produce a variety of mediators. Laboratory and human studies have shown that
there are at least three important cytokines which are released both by microglia and
astrocytes after injury: interleukin-ip (IL-1P), tumour necrosis factor a (TNFa) and
interleukin-6 (IL-6)1"3.
These proteins, which function as intercellular communication molecules,
seem to stimulate the reparative process which is termed gliosis. Gliosis, however,
results in further production and release of cytokines by hypertrophied astrocytes and
microglial cells, in addition to mediators released by cells of the peripheral immune
system, such as polymorphonuclear cells, which migrate across a "leaky" blood-brain
barrier. The net result may therefore be further damage to brain tissue. The first part
of this review will focus on the parts played by these cytokines.
Leucocyte adhesion molecules, which are expressed on the surface of
leucocytes and endothelial cells, control the migration of leucocytes into tissue. The
expression of these molecules after brain injury is closely linked to cytokine
production. They are thought to mediate toxicity in two ways: by causing leucocyte
plugging of micro-vessels, and by facilitating the release of toxic superoxides by
polymorphonuclear cells which migrate into brain tissue as a result of adhesion
molecule activity. The second part of this review will focus on the parts played by the
adhesion molecules intercellular adhesion molecule (ICAM)-l , E-selectin, L-selectin
and the integrins in brain injury, and on the evidence linking the cytokines to adhesion
molecule upregulation. Finally I shall discuss whether anti-cytokine or anti-adhesion
molecule therapy may improve outcome after acute brain injury.
THE CYTOKINES
The cytokines are low molecular weight polypeptides which are synthesized
and released by multiple cells types throughout the body. Their actions are numerous
but they act primarily as mediators of the inflammatory process (either pro- or anti¬
inflammatory) and as growth factors. Alternative names for the cytokines and
adhesion molecules discussed in this review are listed in Table 1.1. Many of the
clinical signs which are seen after an acute brain injury (eg pyrexia, neutrophilia and
cerebral oedema, secondary to disruption of the blood-brain barrier) are believed to be
caused by cytokine activity4. Cytokines also stimulate the release of many types of
secondary mediators such as the superoxides, neuropeptides and arachidonic acid
12
Table 1.1 Alternative names for the cytokines and leucocyte adhesion molecules
discussed in this review










Tumour necrosis factor a cachectin
L-selectin endothelial leucocyte adhesion molecule-1 (ELAM-1)
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derivatives, and upregulate the activity of the adhesion molecules. We shall consider
the three cytokines IL-ip, TNFa and IL-6 separately in the following sections, but
there is a great deal of overlap in the functions of these molecules - in particular
between IL-ip and TNFa. Table 1.2 and Figure 1.1 summarise the systemic and CNS
actions of these cytokines.
Interleukin 1(3
IL-ip is the main secreted form of IL-15 and has many diverse actions. It has a
molecular weight of about 17.5kDa, and has been implicated in the pathophysiology
of many disease states, including alcoholic liver disease6, septic shock7 and
rheumatoid arthritis8. There is much interesting laboratory work on IL-1P in brain
injury.
Woodroofe et al. showed a rise in cortical IL-1P in the 24 hours after insertion
of microdialysis probes into rats' brains, thus causing penetrating injury9. This was the
first time microdialysis had been used to measure concentrations of cytokines in vivo;
the advantage of this technique was that it permitted repeated sampling from the same
rat, which was conscious and able to move freely. In a fluid percussion trauma model
in the rat, Taupin et al. showed that IL-1P production increased rapidly to a maximum
at 8 hours post injury, remained increased until 18 hours, and then decreased10. This
model of traumatic brain injury reproduces most of the neuropathological changes
seen in human brain tissue after trauma. The rise in IL-1P was seen earlier than in
Woodroofe's study, and the increase was more transient. This may be because by
14
Table 1.2 - Systemic actions of the cytokines
Cytokine Main systemic actions
IL-1P and TNFa* fever
neutrophilia
increased endothelial permeability





increased TNFa (IL-1P*) and IL-6 release
upregulation of adhesion molecule expression
IL-6 induction of hepatic acute phase response
increased endothelial permeability
actions on B-cells and T-cells
cell growth and differentiation
decreased IL-1 (3 and TNFa
upregulation of adhesion molecules
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Figure 1.1- Cytokine actions within the brain
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using the microdialysis technique, Woodroofe measured only the extracellular pool of
IL-lp immediately surrounding the catheter.
Yan et al. found increased IL-ip mRNA expression in a rat model within
hours of a traumatic brain injury n. This elegant study which incorporated many
techniques of measurement including microdialysis, immunohistochemistry and in situ
hybridization also showed that this increased expression was bilateral and not
restricted to the injured area. Giulian et al. showed that microglia were a source of IL-
ip12, which was a potent stimulant of gliosis13 14. This response was at a later stage
after injury than the changes seen in Yan's study.
Other researchers showed that cerebral IL-ip was acutely increased after
permanent focal ischaemia in a middle cerebral artery occlusion stroke model15, and
that cerebral IL-ip mRNA expression peaked 3 hours after onset of ischaemia1''.
Another study, which used a rat model of cerebral ischaemia, showed a peak in IL-ip
mRNA expression 4 hours after injury17.
Several laboratory studies showed the toxic effects of IL-ip It caused
hypotension in rabbits18 (the combination of IL-ip and TNFa was synergistic),
marked neuronal injury in foetal brain cell cultures19 and potentiated the lethal effects
of TNFa in mice20. In addition to its direct effects, IL-lp acts to stimulate production
of other cytokines, including TNFa21 and in particular IL-6, by both astrocytes and
microglia22"27.
There are fewer clinical studies which have implicated IL-ip in brain injury,
possibly because it is produced mainly in the first hours after injury. Poulton et al.
found increased IL-ip in the cerebral cortex after subarachnoid haemorrhage, and
suggested that this increase may be associated with the development of cerebral
vasospasm'8. This group had the good fortune to have access to human brain tissue
specimens which had been removed during the surgical repair of a ruptured aneurysm.
Tarkowski et al. showed that IL-ip was increased in the cerebrospinal fluid of
patients who had sustained a stroke29, and noted that the degree of increase seen was
high er in those with a major stroke, however numbers of patients was relatively small.
Craig McClain and his research group from Kentucky carried out some of the
first and most important early work on the cytokines in brain injury, in which patients
who had sustained a traumatic brain injury were studied. Their particular interest was
the relationship between cytokine production after injury and metabolic changes seen
in this patient population. They found increased IL-ip in patient ventricular fluid after
a traumatic brain injury3. Although the sample was small (n=12), the group was able
to follow patients through to day 21 after injury.
The evidence available to date shows that IL-ip is produced after primary
brain injury, and suggests that it may be a mediator in the secondary inflammatory
response, which results in further damage to the brain in the hours and days after the
injury. We shall discuss the effects of IL-ip on adhesion molecule expression later in
this review.
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Tumour Necrosis Factor a
TNFa has much in common with IL-1 (3. It too is increased in the serum in
non-neurological disease, such as sepsis30, burns31 32, alcoholic liver disease6 and
multiple trauma33.
Again, most of the studies in this area are experimental: in one of the most
important animal studies of TNFa in traumatic brain injury Shohami et al. showed
increased TNFa in contused rat brain at 1 hour post injury (weight-drop model).
Concentrations peaked by 4 hours and began to fall34. The group also looked at tissue
on the side of the brain contra-lateral to the injury. Positive results were seen at 4
hours, but concentrations were only 10% of those found in the contused hemisphere.
Similarly, in the same study described earlier for IL-ip, Taupin et al. showed
that the maximal increase in TNFa in traumatized rat brain was at 3 hours, and that
concentrations fell to baseline by 18 hours10. In a rat stroke model, Liu et al. showed
that TNFa mRNA expression was induced and detected immunohistochemically in
neurons by 1 hour after the onset of ischaemia35. These findings suggest that TNFa,
together with IL-1P, is released very early after injury, and may go some way towards
explaining why these two cytokines are often not detected in the serum in clinical
studies.
Several investigators have studied the toxic effects of TNFa: one gave either
TNFa or endotoxin to volunteers and showed that both induced a similar metabolic
response including fever, stress hormone and acute phase protein release36. TNFa
infusion in mice caused lymphopaenia, neutrophilia, shock and watery diarrhoea37 and
TNFa administered to neuronal cell cultures caused severe neuronal injury19. These
studies, although of interest, involve the administration of unphysiological
concentrations of the cytokine and therefore the results must be interpreted with
caution.
Kwang Sik Ki et al. gave intra-cisternal injections of TNFa to rats, which
altered blood-brain barrier permeability and increased cerebrospinal fluid white cell
count38. Using an argument similar to that above, this result is important, but perhaps
not quite so important as those studies in which the physiological actions of the
cytokines are blocked by antagonists.
There is evidence to suggest that IL-1 (321 and lipopolysaccharide (LPS,
endotoxin))39 cause increased TNFa production in the CNS, whereas IL-6 causes
decreased production of TNFa by monocytes40, suggesting a negative feedback
process. TNFa itself, in a similar fashion to IL-1 p, causes the release of other
cytokines, particularly IL-622 24"27 41. In a study by Sheron et al. Hepatitis B sufferers
were treated with TNFa, which caused increases in serum IL-6 and IL-842.
In neurological disease, Waage et al. showed that serum TNF was increased in
patients with meningococcal infection, and that the increase was more marked in
those who were hypotensive43. Goodman et al. showed increased serum TNFa in 21
patients after traumatic brain injury; although numbers were small, increased
concentrations of serum TNFa were seen in all of the patients. This is the only human
study to show such large rises in serum concentrations of TNFa after traumatic brain
injury. The group were unable to demonstrate any correlation between serum
concentrations and outcome44. In 1994, Ross et al. showed that TNFa was present in
the serum of 18 out of 50 patients with traumatic brain injury1. Each patient had only
one measurement taken, and so any changes in TNFa seen with time were
unfortunately missed. However 26 had samples of CSF analysed and TNFa was
found in 17 of these.
Again the evidence is strongly suggestive that TNFa is produced in the brain
after injury. It may be an important factor in the propagation of the inflammatory
process in the early stages after a brain injury.
Interleukin-6
Many investigators have studied IL-6 in tissue injury and disease. It is a 26kD
protein which differs from IL-1|3 and TNFa in that it both causes and inhibits
inflammation4 4l). A particularly important function of IL-6 in brain injury is its action
to increase endothelial permeability45. There are many review articles which cover its
functions in detail46"48. Several studies found increased serum IL-6 in non-neurological
disease, particularly in the systemic inflammatory response syndrome30 49 where
mortality was correlated with serum concentrations of IL-6. Serum IL-6 was also
increased in nosocomial infection in the intensive care unit50, after multiple trauma33
and cardio-pulmonary bypass51. In many of these studies, disease severity correlated
with IL-6 concentrations. There has been some debate about whether IL-6 is actually
an active mediator in the inflammatory process or is simply a marker of the severity of
injury52, but the available evidence clearly implicates IL-6 in the pathophysiology of
inflammatory brain injury.
Hariri et al. found increased IL-6 production by astrocytes in a model in which
human astrocyte cell lines were cultured in the laboratory and subjected to a
mechanical injury using fluid percussion barotrauma53. Injury of increasing severity
was related to IL-6 production. Similarly, Shohami et al. showed increased IL-6 in
contused rat brain, which peaked 8 hours after injury34. Other investigators showed
similar increases in IL-6 in trauma models9"11, which usually lagged behind the
production peaks of IL-1(3 and TNFa.
There are many clinical studies which investigate the part played by IL-6 in
brain injury. Osuka et al. investigated the theory that increased serum IL-6 was related
to brain tissue damage and, in an interesting study, measured IL-6 in the serum of 70
patients after neurosurgery. They found a rise which peaked 24 hours after surgery54
and decreased back to pre-operative concentrations over the following 7 days. The
magnitude of the increase was related to the type and duration of the surgery. In a
similar study Heesen et al. showed that serum IL-6 was increased in 20 patients after
craniotomy, peaking 24 hours post-operatively, although they did not go on to
measure serum concentrations of IL-6 after 24 hours55.
In 30 patients with a traumatic brain injury, McClain et al. found increased
serum concentrations of IL-6, which were highest on admission, and highly increased
ventricular fluid IL-6. The fall in serum IL-6 concentration correlated with clinical
improvement, and concentrations fell more rapidly in those with a Glasgow Coma
Score (GCS) greater than eight2. This is one of the most commonly cited papers by
those who believe that IL-6 plays a major role in inflammatory brain injury. In a more
recent study of 22 patients with traumatic brain injury, Kossman et al. found increased
ventricular fluid concentrations of IL-6 and a relationship between IL-6 concentration
and production of nerve growth factor56.
Clinical studies in non-traumatic brain injury further implicate IL-6 as a
mediator in the secondary injury process. Several investigators have studied IL-6 in
stroke patients: Tarkowski et al. found increased IL-6 in the cerebrospinal fluid of 30
stroke patients, with less pronounced serum rises29. This study is notable because
patients were followed up for 3 months. Concentrations peaked at days 2-3, but IL-6
was still present in the cerebrospinal fluid at day 90 after the stroke. There was a
significant correlation between early intrathecal production of IL-6 and the size of the
brain lesion.
Beamer et al. found increased plasma concentrations of IL-6 in 50 stroke
patients, with the highest concentrations in those with large infarcts57 whilst Kim et al.
studied serial plasma concentrations of IL-6 in 29 patients with non-traumatic acute
brain injury and found similar rises which peaked at day 1 but persisted at day 758. In
subarachnoid haemorrhage, cerebrospinal fluid IL-6 was increased, peaking at day 659,
and in another study both IL-6 and IL-8 concentrations were increased in
cerebrospinal fluid60. An interesting study by Amado et al. found that the
concentration of IL-6 in the plasma of patients rose at the time of diagnosis of brain
death61.
As we have already discussed, IL-1J3 and TNFa, together with many other
mediators including platelet activating factor, interferon and the bradykinins62"64,
promote IL-6 production. The part played by IL-6 in the intracranial inflammatory
process is complex, because it has pro- and anti-inflammatory actions, and has a
negative feedback effect on the production of IL-ip and TNFa40(Table 1.2), but it
would appear to occupy a central point in the web of mediators which are involved in
the inflammatory response to brain injury.
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THE CYTOKINES AND THE ADHESION MOLECULES
There are three families of adhesion molecule65. The first includes the
glycoproteins L-selectin and E-selectin, which are present on the surface of leucocytes
and endothelial cells respectively. These mediate the initial tethering of leucocytes to
the vessel wall by binding to endothelial receptors66. Deficiency of either the selectins
or their ligands causes failure of the migration process and recurrent infections67 68.
The other two families mediate strong adhesion and migration across the
endothelium into tissues. The immunoglobulin "superfamily" consists of intercellular
adhesion molecule (ICAM) 1 and 2 and vascular cell adhesion molecule (VCAM) 1,
which are present on the endothelial surface. Their counter-receptors form the third
family, the integrins (eg CD1 lb and CD 18), which are present on the leucocyte cell
surface (Figure 1.2). The blood of healthy humans contains soluble, active forms of
the selectins and immunoglobulins (eg sL-selectin, sICAM-1)69. This review will focus
on those molecules which have been most closely studied in brain injury - namely
ICAM-1, E- and L-selectin and the integrins.
Before we look at the part played by the adhesion molecules in detail, we
should examine the relationship between the cytokines previously discussed and
control of adhesion molecule activity. Experimental work suggests that IL-ip, IL-6
and TNFa all upregulate the activity of these molecules: an early study by Bevilacqua
et al. showed that treatment of cultured human vascular endothelial cells with IL-1 j3
resulted in increased polymorphonuclear cell adhesion by acting on endothelial cells
themselves. Neither pre-treatment of leucocytes with IL-1 nor the addition of IL-1
during the assay affected endothelial-leucocyte adhesion70.
Figure 1.2 - Stages of neutrophil adhesion to, and migration across, the endothelium.
I - initial tethering II - strong adhesion III - migration
E-selectin
26
Duits et al. treated leukaemic cell lines with IL-6 and found increased surface
expression of ICAM-171 and Hutchins et al. reported similar findings in breast cancer
cell lines72. IL-1(3, but not IL-6, increased ICAM-1 expression in rat mesangial cells73
and IL-lp and TNFa induced expression of L-selectin on the activated endothelium
of umbilical vein66. Other investigators showed that IL-ip increased ICAM-1
expression in fibroblasts74 and that IL-1(3 and TNFa increased ICAM-1 expression in
hepatocyte cell lines75.
Hahne et al. showed how diverse the actions of a single cytokine may be when
they discovered that TNFa induced expression of five different types of adhesion
molecule in mouse endothelioma cells: ICAM-1, VCAM-1, E-selectin, P-selectin and
one molecule not previously described76. This complex study is one of the few to look
at the effects of cytokines on the expression of P-selectin, a member of the selectin
family only expressed on vascular endothelium after tissue injury.
There has been little work which has studied any link between IL-6 production
and adhesion molecule expression after brain injury. We therefore have to look to
studies of other diseases for suggestions as to how IL-6 may be involved in adhesion
molecule activation. Kukielka et al. have published considerable findings on the
relationship between IL-6 and the upregulation of ICAM-1 in the pathophysiology of
reperfusion injury in the myocardium77"79. They showed that increased IL-6 mRNA
expression was seen in a canine myocardial reperfusion model, and that this was
followed by an increase in ICAM-1 expression in the same segments. In a clinical
study which examined 22 patients admitted to the intensive care unit with illnesses
resulting from liver cirrhosis, leucocyte expression of the integrins CDllb and CD35
correlated with the concentration of IL-6 in plasma80.
There is certainly evidence that the cytokines are involved in the regulation of
adhesion molecule activity in non-neurological disease, and further experimental
studies which studied brain tissue add weight to this important relationship in brain
injury.
Zielasek et al. found that TNFa and interferon-gamma caused an increase in
ICAM-1 expression over normal baseline expression in isolated rat microglia81.
DoreDuffy et al. studied the effects of TNFa on rat CNS endothelium in vitro and
found increased expression of VCAM-1 and E-selectin; this study was important
because intact endothelium was studied rather than just cultured endothelial cells82. In
a similar study by Wong and DoroviniZis, IL-ip ,TNFa, interferon-gamma and LPS
all increased ICAM-1 expression in primary cultures of human brain microvessel
endothelial cells8'\ In a study in which the investigators had early access to human
brain tissue post-mortem, Rieckmann et al. found that ICAM-1 was mainly expressed
on endothelial cells of small vessels, and showed that expression of ICAM-1 was
increased in tissue sections after stimulation with TNFa and LPS84.
These studies suggest that changes in local concentrations of cytokines seen
after acute brain injury may affect the activity of adhesion molecules in the CNS,
which may then increase polymorphonuclear cell infiltration and cause further cellular
damage (Figure 1.3). We shall now go on to look at the adhesion molecules, and the
part they play in brain injury, more closely.
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Clinical research into the role of the adhesion molecules in disease is
still in its infancy, particularly in the area of acute brain injury, but many studies
suggest that manipulation of the effects of these molecules may prove to be a powerful
tool in the treatment of inflammatory disease. Detailed reviews of the adhesion
molecules can provide additional background information65 85 86. The most extensively
studied molecule is ICAM-1, a member of the immunoglobulin "superfamily" This
molecule is expressed on the vascular endothelium and, as has already been stated,
facilitates strong adhesion and migration of white cells from vessels into tissue. There
is also evidence of its role in the intra-parenchymal binding of white cells to tissue cells
such as astrocytes in the CNS87 88.
The soluble forms of the adhesion molecules (eg sICAM-1) are those which
can be measured by assay in the serum or plasma of normal individuals69, but the part
they play in the physiological response to injury is unclear. Increased serum
concentrations of the soluble endothelial molecules (sICAM-1, sE-selectin) may result
from damage to the endothelium as a result of systemic inflammatory processes.
Alternatively, these same processes may cause an "activation" of the endothelium, with
upregulation of production and shedding of these molecules into the blood89 %.
Again laboratory studies add weight to the evidence provided by the small
number of clinical studies on this subject in brain injury. Hallenbeck et al. and Garcia et
al. showed that polymorphonuclear cells accumulate in damaged brain tissue91 92. The
former group published their work in 1986, having studied a canine model of brain
ischaemia in which granulocyte accumulation was found in the injured hemisphere
within 60 minutes of injury. The latter group used a relatively large sample (n=96) of
rats in their study in which they induced ischaemia by ligating the middle cerebral
artery. They also found evidence of early infiltration of leucocytes - polymorphs were
detected in the microvessels of the injured hemisphere as early as 30 minutes after the
onset of ischaemia. Schoettle et al. found a significant correlation between degree of
polymorphonuclear cell accumulation after brain trauma and extent of cerebral oedema
in rat fluid percussion model93. This group was the first to show a relationship between
leucocyte infiltration and oedema after brain injury.
There is little laboratory work on the adhesion molecules in traumatic brain
injury; most studies examine adhesion molecules in stroke models, although this work
is certainly relevant to all forms of cerebral ischaemia. Wang et al. showed, in a study
using a rat stroke model, and including both Northern blot and sensitive RT-PCR
analysis methods, an increase in cortical E-selectin expression by 6 hours post-injury,
which peaked at 12 hours and returned to basal concentrations by day 5. ICAM-1
expression was also increased by 3 hours post-injury and remained increased for 5
days.94 95.
Clark et al. studied CNS reperfusion injury in rats, with a temporary middle
cerebral artery occlusion model. This important study showed an increase in cortical
ICAM-1 expression from 1 hour post-injury, which persisted for 72 hours. This
correlated with a moderate infiltration of polymorphonuclear cells in the areas of
ICAM-1 expression'^'. Haring et al. studied cerebral reperfusion injury in primates,
using a temporary middle cerebral artery occlusion model, and found an upregulation
of E-selectin in the ischaemic microvessels after injury97.
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In one study looking at a model of subarachnoid haemorrhage in rats, Handa et
al. showed an increased expression of ICAM-1 on cerebrovascular endothelial cells98.
Soriano et al. recently showed that ICAM-1 deficient mice were less susceptible to
cerebral ischaemia / reperfusion injury99. This study is particularly interesting, as the
fact that a genetically engineered deficiency of ICAM-1 reduces susceptibility to the
effects of reperfusion injury provides powerful evidence that ICAM-1 is a factor in the
pathophysiology of reperfusion injury.
Many of the clinical studies on the subject of adhesion molecules carried out to
date have been in the systemic inflammatory response syndrome patient population.
Cowley et al. found increased concentrations of sICAM-1, sVCAM-1 and sE-selectin
in sepsis, particularly if there was organ dysfunction. A high sE-selectin concentration
correlated closely with multiple organ dysfunction and death100. In other studies of
septic patients, sICAM-189 and sE-selectin101 were increased in sepsis (concentrations
of sICAM-1 were significantly higher after 24 hours in non-survivors than survivors).
Patients with multiple trauma have also been studied. Boldt et al. found that
sICAM-1 was increased in sepsis and after trauma, but the rise was greater in the
sepsis group. sE-selectin and sVCAM-1 were increased in sepsis but not in trauma102.
Law et al. showed that a rise in serum SICAM-1 after multiple trauma correlated with
the severity of subsequent multiple organ dysfunction90.
sL-selectin is increased in cerebral malaria103 and in a study which examined
human brain tissue post mortem, ICAM-1 expression was increased in the cerebral
vessels of patients with the diagnoses of multiple sclerosis, viral encephalitis and
cerebral infarct104. Rieckmann et al. found a high concentration of sICAM-1 in the
cerebrospinal fluid of patients with bacterial meningitis and other inflammatory
neurological diseases such as multiple sclerosis and polyradiculitis. Concentrations of
sICAM-1 correlated with measures of blood-brain barrier dysfunction105. sICAM-1
was found in the cerebrospinal fluid of patients with non-inflammatory neurological
diseases such as tumours and degenerative disease in only 3 out of 50 cases (6%).
Jander et al. also showed high cerebrospinal fluid and serum concentrations of
sICAM-1 in bacterial meningitis106.
Kim et al. studied integrin expression on leucocytes from patients with the
diagnosis of stroke or transient ischaemic attack and, although patient numbers were
small (n=16), found increased expression of CDlla and CD18 within 72 hours after
the onset of ischaemia107. Lindsberg et al. studied brain sections of patients who had
died from stroke disease. This is one of the few ways in which human tissue can be
studied in detail. 11 subjects who died between 15 hours and 18 days after sustaining a
stroke were studied. The group showed a striking upregulation of endothelial ICAM-1
in the cerebral microvessels108.
There are no published studies to date which investigate serial changes in
adhesion molecules in traumatic brain injury or spontaneous subarachnoid
haemorrhage, but Keskil reported that in a group of 153 patients with a traumatic brain
injury there was a good correlation between injury grading and admission white cell
count109.
In a recent stroke study, Fassbender et al. found increased sICAM-1 and
reduced sL-selectin in patients with significant risk factors for stroke, and in addition
found increased sICAM-1, reduced sL-selectin, increased sE-selectin and sVCAM-1 in
a group who had sustained a stroke110. This fall in sL-selectin may be explained by the
notion that activated endothelial counter receptors "mop up" the pool of sL-selectin in
serum. A study by Donnelly et al. supported this theory. They found reduced sL-
selectin in the serum of a sub-group of patients who progressed to develop the acute
respiratory distress syndrome from a sample judged to be "at risk" on recruitment to
the study111. Blann et al. proposed a similar theory to explain their findings of a
reduced concentration of sL-selectin in patients with systemic sclerosis and vasculitis.
They also showed an inverse relationship between serum sL-selectin and disease
severity112.
The rather limited evidence available suggests that acute brain injury may result
in an increased expression of leucocyte adhesion molecules on the cerebrovascular
endothelium, and in brain tissue itself, with expression mediated in part by the
cytokines. The final step in the investigative pathway is to examine the effects of
cytokine and adhesion molecule antagonists on the process, and to examine whether
these compounds may offer a potential benefit after brain injury.
ANTICYTOKINE AND ANTIADHESION MOLECULE THERAPY
There are several questions to be answered in the final part of this review.
What effects do anticytokine therapies have on cerebral tissues and expression of
adhesion molecules after acute brain injury? Do antibodies to adhesion molecules
reduce secondary damage after a cerebral insult? What effects do these potential
therapies have in injuries to other organ systems?
Let us consider the last question first. Few physicians in the specialities of
anaesthesia or intensive care will be unaware of the interest in anticytokine therapy in
the management of the systemic inflammatory response syndrome in recent years, and
the reporting of findings of several multicentre trials. Fisher et al. published the findings
of two trials in 1993 and 1994. The first looked at treatment of the systemic
inflammatory response syndrome with anti-TNFa antibody and showed no apparent
benefit"3. The second examined the effects of an IL-ip receptor antagonist (IL-ipra)
and showed no increase in survival in the treated group"4.
In 1996, Cohen et al. reported the findings of the "Intersepf trial in which 564
patients with the systemic inflammatory response syndrome were randomised to
receive TNFcx antibody therapy or placebo"5. Again there was no significant difference
in mortality, but the treated group showed a more rapid reversal of shock and a longer
time until first organ failure.
These findings do not encourage optimism in those who hope that anticytokine
therapy may aid acute brain injury management, but there has been some criticism of
the design of these studies and it may be that significant treatment effects were missed.
We must remember that the cytokines function as natural communication molecules in
host defence, and so antagonism may also have detrimental effects.
In experimental anticytokine therapy in the laboratory, however, findings are
more encouraging. Giulian et al. showed that in glia-neuron co-cultures, activated
microglia produced soluble factors which increased the population of microglial cells
and reduced numbers of neurons. IL-ipra blocked this astroglial proliferative effect116.
Studies of this type, in which antagonists to a cytokine or adhesion molecule block a
particular pathophysiological process, either in vitro or in vivo, offer some of the most
powerful evidence available for the involvement of these molecules in brain injury.
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Kwang Sik Ki et al. showed that the increase in blood-brain barrier permeability
and cerebrospinal fluid white cell count caused by the administration of intra-cisternal
TNFa was abolished by treatment with a TNFa antibody38. Chao et al. gave IL-ip and
TNFa together to foetal brain cell cultures. Administration of both nitric oxide
inhibitors and NMDA receptor antagonists reduced the resultant marked neuronal
injury19. Although both are interesting studies, the fact that cytokines have been
artificially introduced to the experimental environment in doses likely to be above those
seen physiologically weakens their value.
Two studies examined the effects of anti-cytokine therapy on cerebral oedema:
Yamasaki et al. showed that in a rat middle cerebral artery occlusion model, the
administration of an IL-ip blocker reduced cerebral oedema117; more recently Shohami
et al. showed that after traumatic brain injury in the rat, TNFa antibody therapy caused
a reduction of cerebral oedema at 24hrs post-injury, and facilitated recovery of motor
function"8 Both studies offer a tantalizing glimpse of the therapeutic potential that
some investigators believe these agents may offer.
Toulmond et al. gave IL-lra to rats who had sustained a traumatic brain injury.
In the group where treatment was given immediately after the injury, a reduction in
lesion size, assessed histologically, of 44% was found. Even if treatment was delayed
by 4 hours, a 28% reduction in lesion size was seen119. Shibayama et al. showed that
treatment of mice who had sustained a penetrating stab wound to the brain with
antibody to IL-ip resulted in a significant reduction of ICAM-1 positive glia at 24 and
48 hrs post injury88 and Rothlein et al. showed that cytokine specific anti-sera inhibited
induction of ICAM-1 in adenocarcinoma cell lines by IL-ip and TNFa120. These
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findings would suggest that anticytokine therapy may be capable of reducing cerebral
tissue damage and adhesion molecule expression after brain injury.
Finally, let us consider the therapeutic potential of blocking the actions of
adhesion molecules themselves. This is theoretically a more attractive option than
attempting to block the diverse actions of the cytokines, with their complex inter¬
relationships. Clark and Zivin have recently published a detailed review on this subject
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in stroke , as have Hartl et al. and Chopp and Zhang , but the subject has
received little attention by investigators in traumatic brain injury research.
Two groups have made substantial progress in this area using models of CNS
ischaemia - Chopp and Zhang's group from Detroit and Clark's group from Oregon.
They have published several interesting studies which show the potential of anti-
adhesion molecule therapy in brain injury. In 1991, Clark's group published two good
papers which looked at the effects of two different anti-adhesion molecule antibodies in
two models of CNS ischaemia124 125 - the first a reversible model of spinal cord
ischaemia, the second an irreversible brain ischaemia model. It showed that antibody to
the integrin CD 18 and to the immunoglobulin ICAM-1 produced a significant
reduction in neurological deficits in the former model but not the latter - findings which
implicate leucocytes in CNS reperfusion injury.
The Detroit group has published findings from several well-planned studies in
rat stoke models since 1994; it showed that anti-ICAM-1 antibody reduced infarct size
and polymorphonuclear cell infiltrate in a temporary middle cerebral artery occlusion
model in rats126; in a similar model, anti-CD 1 lb antibody decreased the volume of the
ischaemic lesion, but this was not so in a permanent middle cerebral artery occlusion
model127; antibody to the Mac-1 integrin resulted in decreased weight loss,
neurological dysfunction, polymorphonuclear cell infiltration and infarct size in a
temporary middle cerebral artery occlusion model128, and the group showed that anti-
ICAM-1 antibody decreased infarct size and weight loss in a temporary but not
permanent middle cerebral artery occlusion model129.
In more recent work it has looked at the effect of giving antibodies later than at
the onset of ischaemia - which is much more relevant to the clinical scenario. It showed
that treatment with anti-CD 1 lb and anti CD 18 antibodies 2-4 hours after the onset of
ischaemia resulted in reduced infarct size and decreased myeloperoxidase activity in a
temporary middle cerebral artery occlusion model130 and also showed that treatment
with anti-ICAM-1 and anti-integrin antibodies at time of repeidusion reduced infarct
size and the number of apoptotic cells seen after temporary middle cerebral artery
occlusion131.
Other groups have reported similar benefits: Matsuo et al. showed a reduction
in cerebral oedema, polymorphonuclear cell infiltrate and infarct size after
administration of anti-ICAM-1 and anti-integrin antibody, both at 15 minutes pre-
ischaemia and at reperfusion, in a rat stroke model132. In a spinal cord ischaemia model
in rabbits, Lindsberg et al found that administration of an anti-integrin antibody
reduced motor deficit and blood-brain barrier dysfunction133.
Other antagonists may have a part to play in future anti-adhesion therapy:
Nelson et al. showed that heparin oligosaccharides bind to L- and P-selectin and thus
inhibit their binding to other counter-receptors134; Cecconi et al. showed that inositol
polyanions reduced binding of L- and P-selectin in vitro1,5.
The available evidence therefore suggests that administration of agents which
antagonise the harmful effects of neutrophil adhesion and migration into tissue may be
beneficial, although again we must be aware that adhesion and migration of leucocytes
are natural responses of the host to injury, and that antagonism of these actions may
reduce the positive effects of the inflammatory response.
CONCLUSIONS
Research to date strongly implicates cytokines such as IL-lp, IL-6 and TNFa,
together with the leucocyte adhesion molecules, in the pathophysiological response to
primary brain injury The cascades or webs of mediators released after primary injury
cause secondary brain injury which may be severe. Further work in the areas of
anticytokine and, in particular, anti-adhesion molecule therapy may result in the
development of novel therapies which alleviate the devastating sequelae of acute injury
to the brain.
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I have reviewed the parts played by the cytokines and adhesion molecules in
the pathophysiology of acute brain injury. It is clear from this review that further
clinical research is necessary to investigate the effects of the intracranial inflammatory
process in patients rather than just in the laboratory.
Chapter 2 describes a study carried out in the intensive care unit which
examines serial changes in cytokines and adhesion molecules in patients who have
sustained a brain injury, and relates these to each other and neurological outcome.
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CHAPTER 2
SERUM MARKERS OF CEREBRAL




As I have discussed in Chapter 1, there is much evidence to suggest that both
the cytokines and the adhesion molecules play a pivotal part in the pathophysiology of
the inflammatory process after both traumatic brain injury and spontaneous
subarachnoid haemorrhage. There have, however, been no clinical studies published
to date which look at serial cytokine and adhesion molecule concentrations in either
cerebrospinal fluid or arterial and jugular venous serum after acute brain injury and
relate these to neurological outcome.
There has also been interest in the measurement of neuron specific enolase, an
isoform of the glycolytic enzyme enolase, which is found in neurons and neuro¬
endocrine cells, in the serum and cerebrospinal fluid after brain injury1'16"138. Some
investigators have claimed that the concentration of this substance in serum or
cerebrospinal fluid is a good quantitative marker of neuronal damage. Others have
suggested that measurement of serum or cerebrospinal fluid concentrations of protein
S-100, a protein present predominantly in astroglial cells, after brain injury is a suitable
quantitative marker of injury severity139"142.
With the increased use of intraparenchymal solid state methods for monitoring
intra-cranial pressure, access to cerebrospinal fluid for analysis is often not possible,
and where it is, sampling from catheters may result in ventriculitis141. Placement of a
fibre-optic catheter in the jugular bulb to monitor jugular venous haemoglobin oxygen
saturation is now standard practice within our intensive care unit in patients with acute
brain injury, giving ready access to blood draining from the brain. We investigated the
hypothesis that systemic concentrations of the cytokines IL-1(3, 1L-6, IL-8 and TNFa
and the adhesion molecules sICAM-1 and sL-selectin would be raised after acute brain
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injury, and that increased intracranial production of these molecules would result in a
demonstrable transcranial cytokine gradient, with jugular venous concentrations higher
than arterial. We also investigated whether there was a relationship between serum
concentrations of these molecules and severity of injury as measured by Glasgow
Coma Score and Injury Severity Score, type of injury, protein markers of injury (S-100
and NSE), the presence of extracranial injuries and patient outcome at 6 months after
injury.
METHODS
Local Ethics Committee approval for the study was obtained. A series of 32
sequential patients who had sustained an acute brain injury (traumatic brain injury or
spontaneous subarachnoid haemorrhage) requiring intensive care were recruited to the
study. Informed consent was not obtained as all patients were comatose and therefore
were unable to give consent. Details of the study were discussed with relatives. Data of
patient characteristics, consisting of sex, age, Glasgow Coma Score (GCS) after non¬
surgical resuscitation and Injury Severity Score were recorded on admission to the
intensive care unit (Tables 2.1, 2.2 and 2.3). A single consultant neuroradiologist
classified the brain injury by type from the CT scan. Glasgow Outcome Scores (GOS)
at 6 months after injury were obtained from information supplied by the patients'
general practitioner. The Glasgow Outcome Scores refer to the following: 1 - dead, 2 -
vegetative, 3 - severely disabled, 4 - moderate recovery, 5 - good recovery144.
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Table 2.1 - Characteristics of traumatic brain injury patient group.
Number Sex Age GCS Type of Injury GOS
1 M 22 8 EDH 5
2 M 48 5 ASDH 1
3 M 35 8 EDH 5
4 M 40 5 DI 1
5 F 24 8 Vault fracture U/K
6 M 17 7 HI, hypoxia 4
7 F 49 7 ASDH, DI 4
8 M 21 4 EDH 2
9 F 48 10 Cont + infarct 3
10 M 35 6 HI, hypoxia 4
11 M 19 3 DI 1
12 M 45 3 ASDH 1
13 M 54 3 BOS fracture, tSAH 1
14 M 69 13 Cont + tSAH 1
15 M 19 13 HI 4
16 F 33 11 ASDH 5
17 M 24 6 HI 4
18 M 18 6 Cont 5
19 M 37 7 EDH 3
20 M 17 4 Cont 5
21 M 55 9 HI 5
22 M 18 5 DI + Cont 4
GCS= Glasgow Coma Score GOS= Glagow Outcome Score
EDH= Extradural haematoma ASDH= Acute subdural haematoma
DI= Diffuse Injury Cont- Contusions
tSAH= Traumatic subarachnoid haemorrhage
BOS= Base of skull HI— History of TBI, normal CT scan
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Table 2.2 - Characteristics of subarachnoid haemorrhage patient group.
Number Sex Age GCS GOS
1 M 32 5 3
2 F 51 7 4
3 M 65 6 3
4 F 53 5 3
5 M 38 11 1
6 F 21 7 4
7 M 52 8 4
8 F 55 10 5
9 M 54 3 1
10 M 60 7 1
GCS= Glasgow Coma Score GOS= Glasgow Outcome Score
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Table 2 .3 - Summary of patient characteristics data
TBI (n=22) SAH (n=10)
Sex: Male/Female 18/4 6/4
Age: Range (yrs) 17-69 1(N
Median (yrs) 35 52*
GCS: Range 3 - 13 3 - 11
Median 6 7
GOS: Range 1 - 5 1 - 5
Median 4 3
*= significant difference (p=0.028, t-test)
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A dual lumen Edslab 4-French gauge oximetry catheter (Baxter Healthcare
Corporation, Irvine, CA, USA) was placed in the jugular bulb on the dominant side of
cerebral venous drainage, as previously described145 146. Satisfactory positioning was
ensured by lateral x-ray of the cervical spine (catheter tip seen cephalad to the upper
border of C2 vertebral body), and the correct catheter distance marking (eg 15cm)
showing at the valve of the sheath was written in the notes for future reference. An
intra-arterial catheter was placed (if not already in situ), usually in the radial artery as is
our standard practice.
Paired arterial and jugular venous blood samples were taken at designated
times after brain injury: on admission (median time after injury 8h 30 min, range 2h -
14h), at 24 hours, 48 hours and 96 hours. Time of brain injury in the subarachnoid
haemorrhage group was noted as the time of sudden deterioration in Glasgow Coma
Score by 3 points or more. Patients who did not exhibit a sudden neurological
deterioration were not included. The diagnostic criterion for subarachnoid
haemorrhage was the presence of subarachnoid blood on the CT scan. Satisfactory
positioning of the jugular bulb catheter was ensured before each sample was withdrawn
by checking that the correct distance marker of the catheter was showing at the sheath
valve. No patient underwent craniotomy or siting of an intracranial pressure
monitoring device during the period of observation. Samples were allowed to clot at
room temperature, spun down in a centrifuge at 4000rpm for 10 minutes and the
supernatant removed and frozen immediately at -25 degrees Celsius.
Analysis of serum for IL-1 (3, IL-6, IL-8, TNFa, sICAM-1 and sL-selectin was
performed by enzyme linked immunosorbent assay (ELISA) (Quantikine™ and
Parameter™ Assays, R&D Systems) according to the manufacturer's instructions.
Inter- and intra-assay coefficients of variation for each assay are shown in Table 2.4.
48
Table 2.4 - Performance characteristics of each assay. To assess intra-assay precision,
three samples of known concentration were assayed twenty times on one plate. To
assess inter-assay precision, three samples of known concentration were assayed in
twenty separate assays.
Intra-assay coefficient of Inter-assay coefficient of
variation (%) variation (°/c0
Sample 1 2 3 1 2 3
IL-1|3 3.4 4.4 2.8 8.4 4.2 4.1
IL-6 4.3 1.7 2.1 6.3 3.3 7.2
IL-8 3.9 2.4 3.3 12.2 9.1 7.3
TNF OT¬ 5.2 4.2 4.6 7.4 4.6 5.4
ICAM-1 4.8 4.8 3.3 10.1 7.4 6.0
L-selectin 2.6 4.7 3.1 7.6 5.9 6.3
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Analysis of serum for NSE and S-100 was by radioimmunoassay (RIA) (Sangtec
Medical). All ELISAs were carried out by a single operator using the same equipment
and procedures throughout, as were all RIAs. Repeat freeze-thaw cycles for serum
samples were avoided by separating the serum from each patient into multiple tubes
before freezing. Results for each assay were validated by the inclusion of control sera
supplied by the manufacturer.
A total of 138 samples (69 pairs) were analysed in duplicate for IL-ip, IL-8
and TNFa, with an additional 80 samples (40 pairs) for IL-6, sICAM-1 and
sL-selectin, and results averaged to give the final concentration. Analysis for NSE and
S-100 was carried out on the serum of patients with traumatic brain injury only. Data
are incomplete because of patient death, discharge from the intensive care unit or
values lying outwith ELISA quantification limits. For the traumatic brain injury group,
at each time point n=20, 21,19 and 11 respectively. For the subarachnoid haemorrhage
group, n=10,10, 8 and 6 respectively. Samples which contained a concentration higher
than the highest standard supplied with the kit were diluted and the assay was
repeated. Sera from eight healthy volunteers were analysed for use as controls for the
cytokine assays, and from twelve volunteers for the adhesion molecule, S-100 and
NSE assays. For the ELISAs, standard curves and concentrations were calculated by a
personal computer interfaced to a micro-plate reader using dedicated software (Bio-
Rad Laboratories). For the RIAs standard curves and concentrations were calculated
by a personal computer interfaced to a gamma-counter.
Statistical testing was by means of SPSS Base 7.0 for Windows. P values
quoted are from Wilcoxon rank sum tests, Student's t-tests, one or two way analysis of
variance (ANOVA) and linear or logistic regression analysis. Both parametric and non-
parametric statistical tests are used in this chapter as analysis of the cytokine data was
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carried out at an earlier stage than that of the remainder of the chapter. Statistical
advice at that stage was that as there were some outlying data points, non-parametric
analysis should be used for that data. Advice regarding later analyses was that
parametric methods were appropriate.
RESULTS
Comparing the traumatic brain injury and subarachnoid haemorrhage groups,
patients in the latter group were older (p=0.028), but there was no difference in
Glasgow Coma Score (p=0.979).
The Cytokines
IL-ip, TNFa and IL-8 - IL-ip was undetectable (<3.9pg/ml) in 119 of the 138
samples (86%) assayed The highest concentration in the remaining 19 (14%) was
7.0pg/ml, TNFa was undetectable (<15.6pg/ml) in 122 samples (88%). The highest
concentration in the remaining 16 (12%) was 31pg/ml. IL-8 was detected in 72
samples (52%) (lower limit of detection 94pg/ml), but only 10 (7%) showed
concentrations >300pg/ml. There was no difference between jugular venous and
arterial concentrations of IL-ip, IL-8 or TNFa in those patients with detectable
concentrations. Control samples all showed undetectable concentrations.
IL-6 - IL-6 was detected in all 218 samples. Figures 2.1 and 2.2 show the distribution
of concentrations of IL-6 in the jugular venous and in the arterial samples. In the
controls, concentrations were below detectable limits (<3.1pg/ml) in 4 samples. The
highest concentration in the remaining 4 control samples was 4.7pg/ml. In 4 pairs of
Figure 2.1 - Boxplots comparing median (solid line), interquartile range (shaded area),
outliers (o) and extremes (*) for concentrations of IL-6 in arterial and jugular venous
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Figure 2.2 - Boxplots comparing median, interquartile range, outliers (o) and
extremes (*) for concentrations of IL-6 in arterial and jugular venous samples in
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patient samples (3.7%), both samples showed concentrations >1500pg/ml (the upper
limit of quantification), and were excluded from statistical analysis. In 82 (78.1%) of
the remaining 105 pairs, jugular venous concentration was higher than arterial. In the
traumatic brain injury group, median jugular venous concentration was 74.8pg/ml
(range 19.9 to 539.8); median arterial concentration was 63.5pg/ml (range 11.4 to
518.4) . Median difference was 6.7pg/ml (range -40.8 to 244.4; p<0.001). In the
subarachnoid haemorrhage group, median jugular venous concentration was 64.6pg/ml
(range 19.1 to 455.4); median arterial concentration was 54.1pg/ml (range 12.2 to
407.4). Median difference was 11.3pg/ml (range -32 to 135.2; p<0.001).
Figure 2.3 shows the individual patient profiles for transcranial IL-6 gradient
for each group. In the traumatic brain injury group, median gradients at each time point
were 19.2pg/ml (p<0.001), 10.5pg/ml (p=0.014), 6.3pg/ml (p=0.018) and 1.6pg/ml
(p=0.147) respectively. In the subarachnoid haemorrhage group, median gradients
were 26.8pg/ml (p=0.002), 20.1pg/ml (p=0.027), 5.6pg/ml (p=0.383) and 7.8pg/ml
(p=0.094) respectively. There was no overall difference in IL-6 gradients across the
brain between the traumatic brain injury group and the subarachnoid haemorrhage
group (p=0.350); there were no differences between groups at any of the four sampling
time points (p=0.559, 0.627, 0.832, 0.366 respectively).
The Adhesion Molecules
The data are presented separately for traumatic brain injury and subarachnoid
haemorrhage.
sICAM-1 - Mean arterial concentration at each of the time points following injury is
shown in table 2.5, together with control values from the healthy volunteers.
Concentrations of sICAM-1 were not significantly different from controls in both
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Figure 2.3 - Differences between jugular venous and arterial concentrations of IL-6 in
traumatic brain injury and spontaneous subarachnoid haemorrhage over a 4 day period
post injury.
"I 1 1
Admission 24 Hours 48 Hours
Time after Injury
96 Hours Admission 24 Hours 48 Hours
Time after Injury
96 Hours
Difference between Jugular Venous and
Arterial Concentration of IL-6 (pg/ml)
Difference between Jugular Venous and
Arterial Concentration of IL-6 (pg/ml)
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Tables 2.5 and 2.6 - Mean concentrations of sICAM-1 and sL-selectin in arterial
serum in volunteer controls and patients over a period up to 96 hours after brain
injury. P values are for a two-tailed t-test of patients v controls.
sICAM-1 (ng mf1)
Time Traumatic Brain Injury Subarachnoid Hemorrhage
Mean 95% CI p value Mean 95% CI p value
Controls 254 214-295 - 254 214-295 -
Admission 267 200-335 0.778 283 208-359 0.430
24 hours 269 218-320 0.683 284 217-351 0.385
48 hours 310 252-367 0.154 331 214-449 0.178
96 hours 453 298-609 0.018 437 278-596 0.002
L-selectin (ng ml"1)
Time Traumatic Brain Injury Subarachnoid Hemorrhage
Mean 95% CI p value* Mean 95% CI p value*
Controls 907 808-1006 - 907 808-1006 -
Admission 637 565-709 <0.001 600 498-702 <0.001
24 hours 590 532-647 <0.001 535 467-604 <0.001
48 hours 617 550-683 <0.001 529 424-634 <0.001
96 hours 580 488-672 <0.001 546 454-638 <0.001
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groups on admission, but had risen to concentrations significantly higher than the
controls by 96 hours after injury (p=0.018 for traumatic brain injury, p=0.002 for
subarachnoid haemorrhage). The concentration of sICAM-1 in the traumatic brain
injury group was significantly higher at 96 hours than on admission and at 24 hours
(ANOVA, p=0.006, n=22). There were no significant differences between
concentrations in the subarachnoid haemorrhage group with respect to time (ANOVA,
p=0.080, n=10).
sL-selectin - Table 2.6 shows the mean arterial concentrations of sL-selectin for each
group of patients at each time point, in addition to control data. sL-selectin
concentrations were markedly below controls at all time points in both groups
(p<0.001). There were no significant differences between concentrations of sL-selectin
at any of the time points for either traumatic brain injury or subarachnoid haemorrhage.
There were no significant differences between jugular venous and arterial
concentrations of either adhesion molecule in either patient group. Mean jugular
venous-arterial difference for sICAM-1 in all samples was 6.9ng ml"1 (95% CI [-4.5-
18.3], p=0.310), whilst mean jugular venous-arterial difference for sL-selectin was
3.6ng ml"1 (95% CI [-8.0-15.2], p=0.60). Figures 2.4 and 2.5 show the individual
patient profiles for arterial sICAM-1 and sL-selectin in both groups of patients. There
were no significant differences between the traumatic brain injury and subarachnoid
haemorrhage groups at any time point for arterial or jugular venous concentrations of
sICAM-1 and sL-selectin.
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Figure 2.4 - Profiles of arterial sICAM-1 in the serum of patients with traumatic brain
injury and spontaneous subarachnoid haemorrhage over a 4 day period post injury.
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Figure 2.5 - Profiles of arterial sL-selectin in the serum of patients with traumatic
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Neuron Specific Enolase & Protein S-100
Measurements of these proteins were made in patients with traumatic brain injury only
(n=21 - 1 patient in this group had insufficient serum stored for analysis of NSE and S-
100).
S-100 - Mean jugular venous concentration of S-100 was 1.13 mcg/1 for all patients at
all time points (95% CI [0.59-1.66]), which was significantly higher than the mean
arterial concentration which was 1.05 mcg/1 (95% CI [0.54-1.55], p=0.022) (Figure
2.6). A breakdown of arterial concentrations at different time points, and comparisons
with control samples, are shown in table 2.7. Analysis of variance showed there to be
no significant differences between arterial concentrations of S-100 at different time
points (p=0.90).
NSE - Mean jugular venous concentration of NSE was 11.69 mcg/1 for all patients at
all time points (95% CI [9.81-13.59]). This was not significantly different from the
mean arterial concentration, which was 11.16 mcg/1 (95% CI [9.66-12.67], p=0.416)
(Figure 2.7). Table 2.7 also shows a breakdown ofNSE concentrations by time. Again,
analysis of variance showed there to be no significant differences between
concentrations of S-100 at different time points (p=0.131).
Relationships amongst the cytokines, adhesion molecules and S-100/NSE
Firstly we looked at the relationships between pairs of measurements of the
cytokines and the adhesion molecules at all time points in all patients . There was a
significant positive correlation between transcranial IL-6 gradient and arterial sL-
selectin concentrations (p=0.002, Figure 2.8). There was no demonstrable relationship
between IL-6 gradient and arterial sICAM-1 (p=0.155), between sL-selectin and
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Figure 2.6 - Boxplots comparing median, interquartile range, outliers (o) and
extremes (*) for concentration of protein S-100 in jugular venous and arterial sera in












Jugular venous S-100 Arterial S-100
61
Table 2.7 - Mean concentrations of NSE and S-100 in arterial serum in volunteer
controls and patients over a period up to 96 hours after brain injury. P values are for a
two-tailed t-test of patients v controls.
Time NSE (mcg/1) S-100 (mcg/1)
Mean 95% CI p value Mean 95% CI p value
Controls 6.9 6.3-7.5 ND -
Admission 13.7 10.4-17.0 <0.001 0.80 0.24-1.35 -
24 hours 11.2 8.6-13.7 0.003 1.28 0-2.49 -
48 hours 9.5 6.5-12.5 0.096 1.02 0-2.23 -
96 hours 9.2 5.4-13.0 0.220 1.15 0-2.59 -
*ND = not detected (lower limit of detection 0.2mcg/l)
Patient samples which contained concentrations of S-100 <0.2mcg/l were assigned a
concentration of zero for statistical analysis.
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Figure 2.7 - Boxplots comparing median, interquartile range, outliers (o) and
extremes (*) for concentration of NSE in arterial and jugular venous sera in patients
with traumatic brain injury (p=0.416).
Jugular venous NSE Arterial NSE
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Figure 2.8 - Jugular venous-arterial IL-6 gradient plotted against arterial sL-selectin
for all time points in all patients.
arterial sL-selectin (ng/ml)
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sICAM-1 (p=0.079) or between arterial IL-6 and either sL-selectin or sICAM-1
(p=0.909 and 0.117 respectively).
We then looked at the relationship between the proteins NSE and S-100 and
the cytokines and adhesion molecules in the traumatic brain injury group. There were
significant positive correlations between arterial sICAM-1 and S-100 (p=0.019, Figure
2.9), and arterial NSE and S-100 (PO.OOl, Figure 2.10). There were significant
negative correlations between arterial L-selectin and both NSE and S-100 (p=0.011
and 0.019 respectively, Figures 2.11 and 2.12). The r2 values for these relationships
were generally fairly small however and so their biological significance may not be
important.
Relationships with outcome measures
Patient characteristics. Glasgow Outcome Scores were summarized into two
categories - the first representing a good outcome (GOS 4-5), the second representing
a poor outcome (GOS 1-3). In the traumatic brain injury group there were 12 patients
with a good outcome and 9 patients with a poor outcome (1 lost to follow up). In the
subarachnoid haemorrhage group, 3 patients had a good outcome and 7 had a poor
outcome. There was a statistically significant difference in age between those with
good and poor outcome (mean/standard error of mean was 31.3/3.8 yrs for 'good' and
45.9/3.6 yrs for 'poor', p=0.009), however there was no difference in Glasgow Coma
Score between those with good outcome and those with poor (p=0. 111).
Interleukin 6 and Interleukin 6 gradient: There was no significant relationship
between either arterial IL-6 or transcranial IL-6 gradient and outcome (p=0.225 and
0.555 respectively), controlling for time (general linear model with interaction factor),
in all patients.
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Figure 2.9 - Arterial sICAM-1 plotted against arterial protein S-100 for all time points
in patients with traumatic brain injury.
arterial protein S-100 (mcg/l)
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Figure 2.10 - Arterial NSE plotted against arterial protein S-100 for all time points in
patients with traumatic brain injury.
arterial protein S-100 (mcg/l)
67
Figure 2.11 - Arterial NSE plotted against arterial sL-selectin for all time points in
patients with traumatic brain injury.
arterial sL-selectin (ng/ml)
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Figure 2.12 - Arterial protein S-100 plotted against arterial sL-selectin for all time
points in patients with traumatic brain injury.
arterial sL-selectin (ng/ml)
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Adhesion molecules: There was no significant relationship between arterial sL-selectin
concentrations and outcome (p=0.053), controlling for time, in all patients. There was
a highly significant relationship between arterial sICAM-1 and outcome when all
available time points were considered (p<0.001). Dividing the patients into traumatic
brain injury and subarachnoid haemorrhage groups, sICAM-1 concentrations were
significantly related to outcome in the traumatic brain injury group, but not in the
subarachnoid haemorrhage group, although in the latter group this may be a Type 2
error (p=0.001 and p=0.272 respectively) (Figures 2.13 and 2.14). When only the
concentrations on admission and at 24hrs were considered in the traumatic brain injury
group, there remained a significant relationship with outcome (p=0.014). When we
considered the relationship at only 1 time point (admission) the p value was 0.089.
NSE/S-100: These proteins were measured in the traumatic brain injury group only.
There was a significant relationship between concentrations of both NSE and S-100,
controlling for time, and outcome (p=0.004 and p<0.001 respectively) (Figures 2.15
and 2.16). Significance was still present if the first three time points only were used for
NSE (p=0.014) and if the first two time points only were used for S-100 (p=0.006).
Relationships between injury type and severity, concentrations of IL-6,
sICAM-1, sL-selectin, NSE and S-100, and outcome
As there are several measurements for each patient, a linear model has been
used for statistical analysis here. Figure 2.17 shows the relationship between Glasgow
Coma Score and arterial sICAM-1. There were significantly higher concentrations of
arterial sICAM-1 in those with lower Glasgow Coma Scores (p<0.001). After dividing
the patients into traumatic brain injury and subarachnoid haemorrhage groups, we
found that a highly significant correlation was still seen for the former (p<0.001), but
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Figure 2.13 - Profiles of arterial sICAM-1 in the serum of patients with traumatic
brain injury. Those patients with poor outcome are shown with broken lines, those








admission 24 hrs 48 hrs 96 hrs
time after injury
71
Figure 2.14 - Profiles of arterial sICAM-1 in the serum of patients with subarachnoid
haemorrhage. Those patients with poor outcome are shown with broken lines, those
with good outcome with solid lines.
Arterial sICAM-1 (ng/ml)
time after injury
Figure 2.15 - Profiles of arterial NSE in the serum of patients with traumatic brain
injury. Those patients with poor outcome are shown with broken lines, those with
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Figure 2.16 - Profiles of arterial protein S-100 in the serum of patients with traumatic
brain injury. Those patients with poor outcome are shown with broken lines, those
with good outcome with solid lines. In those where s-100 was undetectable
(<0.2mcg/l) the profile lies on the x-axis.
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Figure 2.17 - Plot showing the relationship between arterial concentration of




the relationship was not significant in the latter (p=0.231, Figure 2.18). Surprisingly,
there was also a negative correlation between arterial sL-selectin and Glasgow Coma
Score (p=0.029). Again when patients were divided into traumatic brain injury and
subarachnoid haemorrhage groups the correlation was significant for the former
(p=0.005), but not the latter group (p=0.280). Again we must consider the possibility
that because of the small number of patients in the latter group that a Type 2 error has
occurred There was no significant correlation between either transcranial IL-6
gradient, arterial NSE or arterial S-100 and Glasgow Coma Score (p=0.191, 0.063 and
0.131 respectively).
We looked more closely at the type and severity of injury in the traumatic brain
injury group, and in particular for the presence of extracranial injuries. 11 patients were
classified as having isolated head injuries and 11 also had extracranial injuries (an
Abbreviated Injury Score of >1 for a body region other than head/neck). There were
no significant differences between these two groups with respect to arterial IL-6,
sICAM-1, sL-selectin, NSE or transcranial IL-6 gradient (p=0.100, 0.221, 0.856,
0.813 and 0.303 respectively). There was, however a significant difference between the
groups for arterial S-100, where the isolated head injury group had significantly higher
arterial concentrations of S-100 than the group with additional extracranial injuries
(mean/SEM = 1.91/0.58 and 0.49/0.13 mcg/1 respectively, p=0.024). There was no
difference in outcome between the groups (p=0.670). The mean Injury Severity Score
was 22.8, SEM 1.43, range 9 - 38. There was no significant relationship between
Injury Severity Score and either arterial IL-6 (Figure 2.19, p=0.063) or sICAM-1
(Figure 2.20, p=0.640), and when, for sICAM-1, only the first two time points were
considered, those patients with a higher Injury Severity Score showed lower
concentrations of ICAM-1, although this did not achieve statistical significance
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Figure 2.18 - Plot showing the relationship between arterial concentration of
sICAM-1 at each time point and Glasgow Coma Score (GCS), for patients with











Figure 2.19 - Plot showing the relationship between arterial concentration of IL-6 and
injury severity score (ISS) for all time points (p=0.063, linear model).
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Figure 2.20 - Plots showing the relationship between arterial concentrations of
sICAM-1 and Injury Severity Score (ISS) for all time points (top, p=0.64, linear






















































(p=0.074). There was a positive correlation between Injury Severity Score and both
arterial NSE and S-100 (Figure 2.21). This was statistically significant for NSE
(p=0.001), but not for S-100 (p=0.155). There was no difference in Injury Severity
Score between good and poor outcome groups (mean/SEM: 23.4/1.9 and 22.0/2.5
respectively, p=0.652).
Finally we looked at type of traumatic brain injury as classified by CT scan.
Scans were categorised into normal, diffuse injury, focal injury, or both. Numbers were
as follows: 3 normal, 8 diffuse, 10 focal and 1 both. Statistical analysis was carried out
excluding "normal" and "both" categories. There was no significant difference between
focal and diffuse groups in outcome (p=0.657) and in either arterial IL-6, sICAM-1 or
sL-selectin concentrations (p=0.767,0.322, 0.801 respectively). Both arterial NSE and
S-100 concentrations were significantly higher in the diffuse group than in the focal
group (mean/SEM: 13.1/1.5 v 9.5/0.7 mcg/1 for NSE, p=0.033, and 1.20/0.31 v
0.26/0.06 mcg/1 for S-100, p=0.006). In contrast, transcranial IL-6 gradients were
significantly higher in the focal group than in the diffuse group (mean/SEM: 31.7/8.5 v
5.9/3.4 pg/ml, p-0.008).
Discussion
We were unable to derive any useful information from the measurement of
either arterial or jugular venous serum concentrations of IL-ip, IL-8 or TNFa at
these time points following acute brain injury. It is generally believed that IL-1 and
TNFa are released in the very early post-injury phase10 34, resulting in increased
synthesis of IL-6, in addition to other mediators. We therefore thought it unlikely that
we would find either IL-ip or TNFa in our samples, but we felt that the study would
be incomplete without measuring them. It may be that we missed an early peak of
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Figure 2.21 - Plots showing the relationship between arterial concentrations ofNSE
(top, p<0.001, linear model) and S-100 (bottom, p=0.155) and injury severity score

















production of IL-ip and TNFa before the patients reached the intensive care unit.
The relatively high lower limit of detection for IL-8 (94pg/ml) in this particular assay
may have masked any significant transcranial gradient. It should also be remembered
that IL-8 is found in erythrocytes and that this may confound attempts to measure its
concentration accurately in serum.
Results for IL-6 show increased jugular venous concentrations of this cytokine
relative to arterial concentrations, particularly within 48hrs of brain injury. Because of
financial limitations it was not possible to further dilute down and re-assay the 4 pairs
of samples in which IL-6 concentrations were greater than 1500pg/ml (these had
already been diluted down and measured a second time). It was therefore necessary to
exclude them from statistical analysis as the IL-6 concentration was not quantified.
The transcranial gradient for IL-6 on admission is around seven times higher
than the highest systemic concentration measured in the controls. This suggests
significant intracranial production of IL-6. The source of this increased production is
likely to be glial cells, and there is experimental evidence to suggest that both
astrocytes53 and microglial cells9 may be involved. In addition, systemic
concentrations of IL-6 were greatly increased. This may be due solely to intracranial
production, but is much more likely to be due to release of IL-6 from extra-cranial
sources ie a mild systemic inflammatory response syndrome. Surprisingly, variation in
the systemic concentrations of IL-6 was unrelated to either the Injury Severity Score
or to the presence of extracranial injuries.
We have been unable to demonstrate any association between either systemic
concentrations of IL-6 or transcranial IL-6 gradient with either good or poor
neurological outcome, thus it may be that intracranial IL-6 production itself does not
result in further neuronal damage. Indeed IL-6 may exert a protective effect as it is
82
known to act to reduce production of cytokines such as TNFa and IL-1 (340 147. It does
however stimulate upregulation of the activity of adhesion molecules77 80, and this may
be relevant when considering IL-6 and outcome.
We have shown that mean systemic serum concentrations of sICAM-1 are
within normal limits shortly after an acute brain injury, but rise in the days following
injury, becoming significantly increased between 48 and 96 hours after injury This is
in marked contrast to the profile of sL-selectin seen in systemic serum following brain
injury. Surprisingly, concentrations of this molecule are significantly lower than
normal values by the time of the first sample (median time 8h 3Qmin following injury),
with concentrations persistently low up to 96 hours after injury. As with transcranial
IL-6 gradient, this pattern is similar in both traumatic brain injury and subarachnoid
haemorrhage suggesting that, despite the different aetiology of the primary injury, the
pathophysiology of the underlying inflammatory process may be similar in these
conditions.
It is generally accepted that cytokines such as IL-1148, tumour necrosis factor
Gt,87 148 149, IL-680 150 151 and IL-8, are factors which regulate adhesion molecule activity.
The significant differences shown between jugular venous and arterial concentrations
of IL-6, were not evident however for either of the adhesion molecules studied, with
jugular venous and arterial concentrations being remarkably similar. This suggests that
changes in intracranial adhesion molecule activity may be the result of a systemic
inflammatory response, in addition to that produced intracranially. Of course we
cannot state that there is a simple relationship between the concentrations of soluble
adhesion molecules present in the serum, and the activity of the membrane bound
forms.
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We can speculate as to the pathophysiological mechanisms behind the observed
changes in adhesion molecule concentrations. It may be that ongoing damage to the
endothelium, secondary to the inflammatory process, results in release of membrane
bound receptors such as ICAM-1 into the blood, causing a rise in measured sICAM-1.
Alternatively, upregulation of ICAM-1 production, for instance as a result of
increased local concentrations of cytokines, may result in increased shedding of these
receptors into the blood. These may then act to limit further adhesion by binding to
leucocyte integrins and function as a type of negative feedback mechanism. The
reduction in sL-selectin that we have shown may be caused by its binding to the
glycoprotein endothelial counter-receptors, such as sialyl Lewis X (sLeX), on
endothelium which has been "activated". Again this may be part of a negative
feedback mechanism, preventing leucocyte bound L-selectin from binding to sLeX.
This hypothesis is supported by the work of Spertini et al152, who showed
experimentally that sL-selectin inhibits binding of neutrophils to endothelium in a dose
dependent manner.
Although we were unable to show any relationship between IL-6 (either
arterial or transcranial gradient) and sICAM-1, the significant positive correlation
between IL-6 gradient and arterial concentrations of sL-selectin is of interest. Looking
at the initial results we expected to see a negative correlation ie high intracranial IL-6
production causing reduced serum sL-selectin. However, in those patients in whom
IL-6 gradients were highest, concentrations of sL-selectin were least reduced from
normal. This may again indicate that IL-6 production is in fact an attempt by the brain
to antagonise the inflammatory cascade.
We showed that there is a highly significant relationship between arterial
concentrations of sICAM-1 and good/poor neurological outcome. Although we
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cannot show that this is a cause and effect relationship, it is a new and important
finding, as rather than merely being a marker of injury, ICAM-1 is known to be a
mediator of inflammation. By antagonizing the actions of ICAM-1, it may be possible
to limit inflammatory secondary damage and improve patient outcome, as I have
discussed at length in Chapter 1. Although mean sICAM-1 concentrations were
normal on admission, Figure 2.13 shows that all patients with an admission or 24 hr
concentration greater than 380 ng/ml had a poor outcome. The differences between
the 48 hour and 96 hour samples are also of interest. There are only 18 patients with
measurements at these time points and the result is not statistically significant, but
looking at the profiles there is always a rise in sICAM-1 between these two time
points in those with poor outcome.
It could be argued that the presence of extracranial injuries would result in
both an increase in arterial sICAM-1 and a greater chance of a poor outcome. This
was not the case in our sample - there was no correlation between Injury Severity
Score and outcome, and in fact those with a higher Injury Severity Score had lower
arterial concentrations of sICAM-1. Increased concentrations of sICAM-1 could not
be explained by the presence or absence of extracranial injuries. This suggests that the
significant increase in arterial sICAM-1 is caused by the brain injury itself, and this is
supported by the fact that there is a highly significant negative correlation between
arterial sICAM-1 and Glasgow Coma Score. Measurement of sICAM-1 on admission
and at 24 hours after a brain injury may assist in prediction of neurological outcome.
This study supports previous work which claimed that serum NSE and protein
S-100 concentrations were indicators of severe brain damage. Protein S-100 is an
astroglial specific protein, and consists of two sub-units, a and p.The two forms
measured in this study were the PP form, found in high concentrations in glial cells
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and Schwann cells, and the a(3 form, found mainly in glial cells. Figure 2.16 shows
that any patient in whom serum arterial S-100 was found to be above 0.9 mcg/1 had a
poor outcome. S-100 was undetectable in only 2 patients with poor outcome. It is
interesting to note that patients with an isolated head injury had higher arterial
concentrations of S-100 than patients with additional extracranial injuries. This may
suggest that the brain injury itself was more severe in the group with isolated head
injury. Serum concentration of NSE, an enolase restricted mainly to neurons and
neuroectodermal tissue, and to some tumours, was also significantly related to
outcome, although not as strongly as S-100. These proteins can be regarded as
markers of brain damage. Concentrations of S-100 were highly correlated with NSE
(r=0.619, p<0.001), and used together in a logistic regression model they are both
independently highly predictive of poor/good outcome (p=0.002 and 0.027
respectively). However, as markers they are purely diagnostic or predictive tools -
they are not open to manipulation or antagonism in a therapeutic sense.
Of much greater interest from the intensive care physician's point of view is
any relationship between the adhesion molecules and NSE/S-100, a significant
relationship adding weight to the suggestion that variations in serum adhesion
molecule concentrations are associated with brain damage, and opening the window
to possible drug therapies. Looking at this in our sample, it is evident that arterial
concentrations of sICAM-1 are indeed significantly positively correlated with arterial
concentrations of S-100, although not to NSE. In addition, both S-100 and NSE are
significantly negatively correlated with arterial concentrations of sL-selectin (which
fall after brain injury). These exciting results suggest that ICAM-1 in particular may
be a suitable target for pharmacological antagonism in brain injured patients in the
future.
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It is apparent that antagonism of the mediators of the inflammatory process
may play a part in future treatment of patients who have sustained an acute brain
injury in the intensive care unit. Currently there is no therapeutic agent available to the
intensive care physician which has been shown to be of benefit in improving outcome
after an acute brain injury.
One management method currently employed in some intensive care units
which may result in improved oxygenation of the brain after acute brain injury is
"controlled hypertension" which involves administration of a pressor agent to raise
mean arterial blood pressure to supra-normal values, and hence increase the cerebral
perfusion pressure.
In the following chapter I report on the results of a study which examined
indices of cerebral oxygen metabolism and blood flow in patients treated with




HYPERTENSION IN THE MANAGEMENT
OF ACUTE BRAIN INJURY -
OBSERVATIONS OF CEREBRAL BLOOD
FLOW, METABOLISM AND OUTCOME
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INTRODUCTION
Cerebral blood flow (CBF) is normally coupled to and regulated by the
cerebral metabolic rate for oxygen (CMR02) and functional glucose utilization153. If
cerebral metabolic requests increase, as during seizures or fever, the cerebral blood
flow increases, so that the ratio between the cerebral metabolic rate for oxygen and
the cerebral blood flow remains constant (CMR02 / CBF = AVD02 where AVD02 is
the arterio-jugular venous difference for oxygen).
In patients with a traumatic brain injury, the cerebral metabolic rate for
oxygen is often reduced154 155 (the normal value is 3.4 ml/lOOg/min (1.5 pmol/g/min)).
Many of these patients have impaired homeostatic regulation of blood flow156, and
several studies157"159 have shown wide variations in cerebral blood flow that are
independent of the cerebral metabolic rate for oxygen. Lassen described such a
dissociation between cerebral blood flow and metabolism as the "luxury perfusion
syndrome"160. This syndrome is defined as excessive blood flow relative to the
metabolic requirements of the brain (also known as cerebral hyperaemia).
Many authors have shown that in patients with a traumatic brain injury,
reduced cerebral blood flow may cause ischaemia157. Miller proposed that cerebral
ischaemia is the single most important cause of secondary brain injury after severe
head trauma161, a theory which was supported by the work of Jones et al.162. There is
also histological evidence that ischaemic brain damage is common in patients with a
traumatic brain injury who die163. Marmarou et al. analyzed The Traumatic Coma
Data Bank and showed that mortality and morbidity caused by severe traumatic brain
injury were strongly related to raised intracranial pressure (ICP > 20 mmHg) and
hypotension (mean arterial pressure = MAP < 80 mmHg)164. As a result, some groups
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now manage patients using a "cerebral perfusion pressure (CPP = MAP - ICP)
management" approach rather than treating intracranial pressure in isolation, with
emphasis on increasing arterial pressure.
Rosner et al. suggested that intracranial pressure wave behaviour is a function
of unstable cerebral perfusion pressure when autoregulation of the cerebral vascular
bed is relatively intact165. They suggested that if cerebral perfusion pressure was kept
above a threshold value, periods of increased intracranial pressure classified as
"plateau waves" could be avoided, and described a model of a "complex vasodilatory
/vasoconstriction cascade" that is the basis for their cerebral perfusion pressure
management protocol166. In this treatment regimen cerebral perfusion pressure is
iatrogenically increased by inducing systemic hypertension.
The traditional view has been that treatment of traumatic brain injury with
controlled systemic hypertension is potentially harmful because vasoparalysis, or
abnormalities of autoregulation, is predominant in patients with traumatic brain
injury167 168. Many believed that controlled systemic hypertension would potentiate
uncontrollable intracranial hypertension. However, in these studies vasoparalysis
occurred at very low cerebral perfusion pressures (10-20 mmHg).
A management protocol for traumatic brain injury which includes induced
arterial hypertension is therefore similar to "triple H therapy" (hypertension,
hypervolaemia and haemodilution)169 for management of spontaneous subarachnoid
haemorrhage. The latter method is now commonly used in the treatment of
subarachnoid haemorrhage. The pathophysiological features of traumatic brain injury
and subarachnoid haemorrhage are similar (as seen in Chapter 2) with broadly similar
outcomes: a third of patients die, a third recover but are functionally impaired and a
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third recover to independence. We have therefore included patients with traumatic
brain injury and patients with spontaneous subarachnoid haemorrhage in this study.
The purpose of this observational study was to assess whether the use of
controlled hypertension in our intensive care unit had adverse effects (such as
increasing the incidence of cerebral hyperaemia) by examining cerebral blood flow
and its relationship with metabolism, together with outcome, in a group of patients
with an acute brain injury treated with controlled hypertension.
METHODS
Patients characteristics and management
Thirty two adults who had sustained either a severe closed traumatic brain
injury (Glasgow Coma Score (GCS) of 8 or less without eye opening) or a
spontaneous subarachnoid haemorrhage admitted to the intensive care unit at the
Western General Hospital were studied. The study population included a significant
number of those studied in Chapter 2. The diagnostic criterion for inclusion in the
latter group was presence of subarachnoid blood on CT scanning Data which
included patient sex, age and Glasgow Coma Score after non-surgical resuscitation
were collected. In addition Glasgow Outcome Scores (GOS) at 6 months after injury
were obtained from information supplied by the patients' general practitioner. The
Glasgow Outcome Scores refer to the following: 1 - dead, 2 - vegetative, 3 - severely
disabled, 4 - moderate recovery, 5 - good recovery144.
All the patients were managed using a protocol that emphasised prevention of
secondary insults to the brain162 170. Patients were intubated and ventilated to maintain
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an arterial partial pressure of oxygen (pa02) greater than 13 kPa and an arterial partial
pressure of carbon dioxide (paC02) of approximately 4.5 kPa.
Arterial haemoglobin oxygen saturation, ECG, rectal and peripheral
temperature, systemic arterial pressure, central venous pressure and intracranial
pressure were continuously monitored. The latter was monitored using an
intraparenchymal fibreoptic catheter (Camino) transducer171. If hydrocephalus was
detected in patients with subarachnoid haemorrhage, intracranial pressure was
monitored with a ventriculostomy catheter (to allow CSF drainage) coupled to an
external transducer system. Invasive systemic haemodynamic monitoring was
universal and if clinical management dictated, the central venous catheter was
replaced by a pulmonary artery catheter. Monitoring also included a fibreoptic
catheter (Explorer System, Baxter Health Care Corporation, Irvine, CA, USA) in the
internal jugular vein on the dominant side of cerebral venous drainage172, positioned
so that the tip was above the upper border of cervical vertebra C2 (confirmed
radiologically). Cerebral venous haemoglobin oxygen saturation was displayed
continuously.
Sedation and analgesia were given intravenously (alfentanil, 0.02 mg/kg/hr
and midazolam, 0.07 mg/kg/hr) and if necessary a neuromuscular blocking agent was
also infused (atracurium, 0.5 mg/kg/hr). Cerebral perfusion pressure was calculated as
the arithmetic difference of the mean arterial pressure and the mean intracranial
pressure, with the patient nursed flat. The threshold value for active cerebral
perfusion pressure treatment was 70 mmHg. We aimed to establish and maintain
isovolaemia or moderate hypervolaemia - a central venous pressure of 10-12 mmHg
or pulmonary artery wedge pressure of 14-16 mmHg was used as a guideline. In
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patients with subarachnoid haemorrhage this clinical management met the criteria for
"triple H therapy".
In a proportion of patients a vasopressor (noradrenaline, adrenaline or
methoxamine) was infused to maintain a cerebral perfusion pressure of at least 70
mmHg166. Every effort was made to minimize the dosage of vasopressor to reduce
possible side effects. Mannitol was given in some patients (together with frusemide
and a plasma expander) with intracranial hypertension, mainly for its haemodynamic
and microrheological effects, rather than to effect cerebral dehydration17 \
Barbiturates were given only if intracranial hypertension was refractory to this
regimen. Cerebral blood flow measurements were not made during barbiturate
infusion.
Physiological measurements
Cerebral blood flow, together with arterial and jugular venous haemoglobin
oxygen saturation, lactate and glucose, was measured at least daily during the period
of intracranial pressure monitoring (range of measures 0-4 days after injury) . A total
of 79 measurements of cerebral blood flow (range 1-7 per patient) were made
Cerebral blood flow was measured by the nitrous oxide saturation method174
with the modification described by Scheinberg175. 3% nitrous oxide was introduced
into the patient's inspired gases via the low pressure inlet of a Servo Ventilator
(900C, Siemens, Sweden) and a continuous side-stream infrared monitor
(Capnograph II, Datex, Helsinki, Finland) was used to check that the nitrous oxide
administration rate was constant throughout the ten minute period required for brain
tissue to become saturated with nitrous oxide. During the ten minutes of gas
inhalation, simultaneous samples (called "arterial integrated" and "venous integrated"
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respectively) were drawn continuously from the radial artery and jugular bulb into
pre-heparinized syringes at the rate of 0.86 ml/min. Accuracy was maintained during
aspiration by placing the two syringes in a parallel infusion/withdrawal pump
(Harvard Apparatus Ltd., Edenbridge, UK). When collection of the integrated
samples was complete, administration of nitrous oxide was continued for another 10
seconds whilst 4 ml samples (called respectively "arterial final" and "venous final")
were withdrawn simultaneously from the artery and the jugular vein.
After ten minutes of nitrous oxide inhalation, the internal carotid blood and
brain nitrous oxide concentrations should be in diffusion equilibrium, and thus the
final venous sample represented the cerebral nitrous oxide concentration175. The final
arterial sample was an internal check of the veracity of the procedure. This
measurement should be in close agreement with the final venous sample if equilibrium
between arterial and cerebral tissue is present. We then injected each blood sample
through a gas tight butyl rubber septum into a 20 ml glass (pre-vacuumed) vial using
a 25 gauge hypodermic needle; the blood samples were kept at room temperature
until the nitrous oxide concentration was measured. To ensure that nitrous oxide in
the gaseous phase was in equilibrium with that in the blood sample, a vortex was
created by agitating each vial for 30 seconds (Vortex Genie 2 Mixer, Merck
House)175. The gas above the blood sample in the vial was then sampled and its
nitrous oxide concentration measured by an infrared analyzer (Nitrous Oxide
Analyzer, ADC Series 7000, Analytical Development Co, Ltd, Hoddesdon, UK) with
an accuracy to within 1 part per million.
Cerebral blood flow was then calculated according to the following equation:
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CBF =[ Fv / (Ai -Vi) x time ] x 100
The numerator is the cerebral venous concentration in parts per million at equilibrium
(Fv); the denominator is the difference between arterial and venous integrated
samples in parts per million multiplied by the time of "wash in" (duration of
aspiration of integrated samples). Multiplication of the result by 100 gave the cerebral
blood flow in units of mls/lOOg/min. We obtained simultaneous arterial and jugular
venous samples at the end of the ten minute period for measurement of pa02, paC02,
pH, haemoglobin, glucose and lactate concentrations and haemoglobin oxygen
saturation. Pa02, paC02 and pH were measured with a Corning blood gas analyzer
(Ciba Corning Diagnostic Ltd, Halstead, Essex, UK). Flaemoglobin concentration and
haemoglobin oxygen saturation were measured with a Corning 270 laboratory co-
oximeter (Ciba Corning Diagnostic Ltd, Halstead, Essex, UK). Blood lactate and
glucose concentrations were measured with a lactate-glucose analyzer (YSI
Incorporated Yellow Springs, Ohio, USA).
The cerebral metabolic rate for oxygen was calculated by multiplying the
cerebral blood flow by the arterio-jugular venous difference for oxygen. The normal
arterio-jugular venous difference for oxygen is 6.3 ml/dl (2.8 pmol/ml)154; the normal
cerebral metabolic rate for oxygen determined by this method is 3 .4 ml/lOOg/min (1.5
(amol/g/min). The lactate-oxygen index (LOI) was calculated with the following
equation:
LOI = -AVDL / AVD02
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where AVDL is the the arterio-jugular venous difference for lactate (both AVDL and
AVDO2 are expressed in molar units). The lactate-oxygen index is normally less than
0.03, whilst values of 0.08 or more indicate increased cerebral lactate production154.
The cerebrovascular resistance (CVR, which indicates vascular tone) was also
calculated using the formula:
CVR = CPP / CBF
Reliable cerebral blood flow measurements require a physiological steady-
state for at least 10 minutes and therefore to avoid delay in cerebral perfusion
pressure management, studies were performed only during periods of stability.
We also carried out transcranial Doppler ultrasound insonation (EME TC2 -
64 B Uberlingen, Germany) of the middle cerebral artery during measurement of
cerebral blood flow, using the method described by Aaslid et al.176, on the same side
of the head as the intracranial pressure monitor was situated. We chose the depth of
insonation that gave the highest mean flow velocity, and took measurements from an
average of at least 15 cardiac cycles. The average mean flow velocity from the middle
cerebral artery measured in our unit was 60 ± 7 (SD) cm/sec177. In patients with a
brain injury, the mean flow velocity was considered abnormally high if it exceeded
100 cm/sec.
Reproducibility of measurement of nitrous oxide concentration in blood
We determined the reproducibility of the measurement technique in five
subjects by taking 10 separate blood samples from the arterial and jugular venous
catheters during the period of administration of nitrous oxide, after saturation of the
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brain with nitrous oxide. To determine the within patient variability of the procedure,
we then fitted a one-way analysis of variance model to remove patient difference,
leaving a residual standard deviation of 3.65ppm. When divided by the fitted mean
value of 112.8ppm, this gave a coefficient of variation of 3.2%.
Classification of measurements and patients
Measurements of cerebral blood flow were corrected, assuming a 3% change
in cerebral blood flow per mmHg change in paC02155, and normalized to a paC02 of
4.5 kPa (34 mmHg). The arterio-jugular venous difference for oxygen also varies
with arterial carbon dioxide tension, and therefore was corrected by the same factor.
The normal arterio-jugular venous difference for oxygen at a paC02 of 4.5 kPa (34
mmHg) is 6.3 + (6 * 0.03 * 6.3) = 7.4 ml/dl, where "6" represents the difference
between normal arterial paC02 and the target arterial paC02 (40 - 34) for our patients
in mmHg.
As cerebral hyperaemia is defined as "blood flow in excess of metabolic
requirements", our primary classification of measurements was by the arterio-jugular
venous difference for oxygen. If cerebral metabolism and blood flow are coupled, an
inverse relationship between the arterio-jugular venous difference for oxygen and
cerebral blood flow should exist. When cerebral blood flow is reduced relative to
metabolic demand, a wide arterio-jugular venous difference for oxygen is found, until
a threshold of 9 ml/dl is reached, which suggests hypoperfusion. If cerebral blood
flow is in excess of metabolic demand, the arterio-jugular venous difference for
oxygen is narrow. Each measurement (n=79) was classified by the value of the
arterio-jugular venous difference for oxygen: hyperaemia was defined as an arterio-
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jugular venous difference for oxygen of less than 4 ml/dl; non-hyperaemia was defined
as an arterio-jugular venous difference for oxygen of greater than 4 ml/dl178.
In addition, individual patients (n=32) were categorized as hyperaemic if one
or more of the measured arterio-jugular venous differences for oxygen was classified
as hyperaemic during the study period. If all measurements of arterio-jugular venous
differences for oxygen were in the non-hyperaemic classification, the patient was
categorized as non-hyperaemic.
All results are expressed as mean ± standard error of the mean. Inter-group
comparison was by one-way analysis of variance (ANOVA) or Fisher's exact test for
two by two tables. Statistical analysis was carried out with "SPSS Base 7.0 for
Windows".
RESULTS
Data of patient characteristics are shown in Table 3.1. Study patients with
subarachnoid haemorrhage were significantly older than those with a traumatic brain
injury. A mass lesion was detected in 31% of patients with traumatic brain injury. The
data for both subarachnoid haemorrhage and traumatic brain injury are presented
together in a similar manner to that of Robertson et al.156.
Cerebral perfusion pressure and cerebral blood flow
A primary goal in clinical management was to avoid systemic hypotension,
and active treatment to increase cerebral perfusion pressure was started if cerebral
perfusion pressure fell below 70 mmHg. At the time of the study most of the patients
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Table 3.1 - Characteristics of the 32 patients studied. Data are expressed as
mean ± SEM.
TBI SAH
sex (M/F) 15/4 8/5
age 37 + 4 50±4t
CTM score I - II n=13
CTM score mass lesion n = 6
GCS on admission 6 + 1 7+1
Definition of abbreviations:
TBI = traumatic brain injury
SAH = subarachnoid hemorrhage
CTM score = computed tomography Marshall score
GCS = Glasgow Coma Scale
t t-test (p = 0.03)
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had a cerebral perfusion pressure of between 70 and 120 mmHg. There was no
demonstrable relationship between cerebral perfusion pressure and cerebral blood
flow, but this was to be expected from the autoregulatory curve.
A vasopressor was used during 56% of measurements (Table 3.2). In those
being treated with a vasopressor, 32.4% of measurements of arterio-jugular venous
differences for oxygen were classified as hyperaemic, compared with 24.1% of those
not being treated with a vasopressor. This difference was not statistically significant
(p=0.586). There was no evidence of ischaemia by either arterio-jugular venous
difference for oxygen or cerebral blood flow measurement criteria153 156 (Table 3.3).
This result was supported by the fact that the lactate oxygen index did not show
increased cerebral lactate production in any case.
Hyperaemia v non-hyperaemia (measurements)
The comparison between hyperaemic and non-hyperaemic measurements is
presented in Table 3 .3. The two measurement groups were equivalent with respect to
cerebral perfusion pressure, intracranial pressure, mean arterial pressure and mean
flow velocity. PaC02 was higher in the hyperaemic measurement group but this was
not statistically significant. Similarly, cerebral blood flow was higher in the
hyperaemic measurement group, but this did not achieve statistical significance.
Although the mean flow velocity was similar in hyperaemic and non-hyperaemic
measurement groups, both were higher than the normal reference range (46-74
cm/sec). This supports the findings of Chan et al.178 and confirms that it is common to
find increased mean flow velocities in patients with acute brain injury.
The lactate oxygen index was significantly different between measurement
groups, but in both groups it was lower than the limit previously described for
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Table 3.2 - Relationship between hyperaemia and vasopressor treatment. Data was
not available for 13 measurements.
Hyperaemic Non-hyperaemic Total
measurements measurements
Treated with vasopressor 12 25 37
No vasopressor 7 22 29
Total 19 47 66
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Table 3.3 - Comparison of cerebral blood flow and metabolic parameters between







CBF (ml/lOOg/min) 116.7 ± 11.0 93.1 ±7.6 0.081
avdo2: (ml/dl) 3.17 ± 0.14 5.70 ± 0.14 <0.001t
CPP (mmHg) 79.3 ±2.3 79.7 ±2.0 0.895
ICP (mmHg) 17.1 ± 1.7 14.0 ± 1.2 0.158
MAP (mmHg) 96.4 ±3.1 93.8 ± 1.7 0.424
paC02 (kPa) 4.37 ±0.12 4.14 ± 0.01 0.085
CMRO2;(ml/100gr/min) 3.74 ±0.38 8.38 ± 1.72 0.01 It
LOI (pmol/ml) -0.030 ±0.014 0.005 ±0.008 0.015t
MFV (cm/s) 87.1 ±10.5 89.2 ±7.4 0.897
CVR (mmHg/1 OOg/min 0.80 ±0.07 1.02 ±0.09 0.043t
Definition of abbreviations:
CBF = cerebral blood flow
AVD02 = arterio-jugular venous oxygen difference
CPP = cerebral perfusion pressure
ICP = intracranial pressure
MAP = mean arterial pressure
paC02 = arterial partial pressure of carbon dioxide
CMRO2 = cerebral metabolic rate of oxygen
LOI = lactate oxygen index
MFV = mean flow velocity
CVR = cerebral vascular resistance
CBF and AVD02 are corrected for PaC02 = 34 mmHg
t significant results (Student's t-test)
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ischaemia179. The cerebrovascular resistance was lower in the hyperaemic
measurement group, as a result of higher cerebral blood flow measurements, where
cerebral perfusion pressures were similar in both groups. There was also a significant
difference in the cerebral metabolic rate for oxygen between measurement groups. In
normal subjects, cerebral blood flow and arterio-jugular venous difference for oxygen
vary inversely, with a constant cerebral metabolic rate for oxygen, however in the
hyperaemic measurement group, the mean arterio-jugular venous difference for
oxygen was lower per unit cerebral blood flow. The result was that the cerebral
metabolic rate for oxygen in the hyperaemic measurement group was lower than in
the non-hyperaemic measurement group.
Hyperaemia v non-hyperaemia (patients)
Ifwe examine the results when patients are categorized as hyperaemic or non-
hyperaemic we find similar results (Table 3 .4). The main difference is that there was a
significant difference in mean arterial pressure (and hence cerebral perfusion pressure)
between patient groups. Mean arterial pressure was higher in the non-hyperaemic
patients than in the hyperaemic patients (p=0.010).
Coupling between cerebral blood flow and metabolism
If coupling between blood flow and metabolism is preserved, an inverse
relationship between arterio-jugular venous difference for oxygen and cerebral blood
flow is evident. Our data confirmed this relationship in the non-hyperaemic
measurement group, in accordance with cerebral blood flow and arterio-jugular
venous difference for oxygen parameters (Figure 3 .1). There is an inverse relationship
between cerebral blood flow and arterio-jugular venous difference for oxygen on the
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Table 3.4 - Comparison of cerebral blood flow and metabolic parameters between
patients categorized as hyperaemic and non-hyperaemic (n=32). Data are expressed






CBF (ml/lOOg/min) 109.3 ±8.4 90.1 ±9.5 0.145
avdo2- (ml/dl) 3.94 + 0.20 5.95 ±0.15 <0.001t
CPP (mmHg) 75.4 + 1.8 83.9 ±2.4 0.006t
ICP (mmHg) 15.4 ± 1.3 14.6 ± 1.6 0.689
map (mmHg) 90.8 ±2.2 98.5 ± 1.6 o.oiot
paC02 (kPa) 4.19 ±0.09 4.23 ±0.08 0.719
cmro2: (ml/100gr/min) 4.16 ± 0.34 9.85 ±2.39 0.023t
LOI (pmol/ml) -0.020 ±0.012 0.001 ±0.010 0.270
mfv (cm/s) 95.7 ±7.2 81.3 ± 10.1 0.250
cvr (mmHg/1 OOg/min 0.82 ±0.06 1.09 ± 0.11 0.040t
Definition of abbreviations:
CBF = cerebral blood flow
AVD02 = arterio-jugular venous oxygen difference
CPP = cerebral perfusion pressure
ICP = intracranial pressure
MAP = mean arterial pressure
paC02 = arterial partial pressure of carbon dioxide
CMR02 = cerebral metabolic rate of oxygen
LOI = lactate oxygen index
MFV = mean flow velocity
CVR = cerebral vascular resistance
CBF and AVD02 are corrected for PaC02 = 34 mmHg
t significant results (Student's t-test)
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Figure 3.1 - Cerebral blood flow (CBF) plotted against arterio-jugular venous
difference for oxygen (AVD02): hyperaemic measurements (AVD02< 4ml/dl) are
shown as solid squares, non-hyperaemic measures (AVD02> 4ml/dl) as open squares.
Dotted lines indicate the normal range for CBF. There is no relationship between the
parameters in the hyperaemic measurement set (p=0.776). There is a negative




right-side of the graph (p=0.042); this relationship is absent in the hyperaemic
measurement group (left-side of the graph).
Cerebral blood flow and cerebral metabolic rate for oxygen
The relationship between cerebral blood flow and cerebral metabolic rate for
oxygen in the two measurement groups is shown in Figure 3.2. The non-hyperaemic
measurement group shows the expected relationship between the two variables and
confirms preserved coupling. The hyperaemic group shows a similar relationship but
this is described by a different fit line. The increased cerebral blood flow
measurements are not related to a change in arterio-jugular venous difference for
oxygen (Figure 3.1) suggesting that "luxury perfusion" is present160.
Cerebral blood flow, metabolism and vascular tone
The relationship between cerebral blood flow and cerebrovascular resistance is
shown in Figure 3.3. All the points are on the same line and show a relationship
between the two parameters described by the following exponential equation:
y = a (Ln)x + b
where y is the cerebral blood flow and x is the cerebrovascular resistance. However,
the hyperaemic measurement group is displaced in the steeper part of the curve
suggesting passive behaviour of the vessels, dependent on the cerebral blood flow.
The relationship between vascular tone (cerebrovascular resistance) and cerebral
metabolism (cerebral metabolic rate for oxygen) is shown in Figure 3.4. The
calculated cerebrovascular resistances of the hyperaemic measurement group are on a
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Figure 3.2 - Cerebral blood flow (CBF) plotted against the cerebral metabolic rate for
oxygen (CMR02). Non-hyperaemic measurements (open squares) show the expected
coupling between cerebral blood flow and metabolism (dashed line, r=0.94, p<0.001).
Hyperaemic measurements (closed squares) show similar behaviour but shifted
upwards (continuous line, r=0.90, p<0.001).
200 T
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Figure 3.3 - Cerebral blood flow (CBF) plotted against cerebrovascular resistance
(CVR). Data points from both measurement groups lie around the same regression
line (r2 = 0.82, p<0.001) but the hyperaemic group (closed diamonds) is displaced
from the non-hyperaemic group (open squares) in the steeper part of the curve.
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Figure 3.4 - Cerebral metabolic rate for oxygen (CMR02) plotted against
cerebrovascular resistance (CVR). Hyperaemic measurement group (closed squares) ;
non-hyperaemic measurement group (open squares).
different curve shifted downwards, indicating a lower level of oxygen extraction for
the same vascular tone.
Patient outcome
Glasgow outcome scores were available for 29 patients and were as follows:
GOS 1 (dead) - 10 patients ; GOS 2 (vegetative) - 0 patients; GOS 3 (severely
disabled) - 10 patients; GOS 4 (moderately disabled) - 5 patients; GOS 5 (good
recovery) - 4 patients. Glasgow Outcome Scores were then summarized into two
categories - the first representing a good outcome (GOS 4-5) - 9 patients, the second
representing a poor outcome (GOS 1-3) - 20 patients.
Looking firstly at the relationship between good or poor outcome and patients
categorized as either hyperaemic or non-hyperaemic, we found no significant
difference between the hyperaemic and non-hyperaemic patient groups (p=1.000). If
we examined the relationship between survival or death and hyperaemia or non-
hyperaemia, there was again no significant difference (p=0.414).
In order to compare good and poor outcome with respect to cerebral blood
flow, arterio-jugular venous difference for oxygen and cerebral perfusion pressure, we
calculated the mean of each parameter for each patient, because each patient had a
variable number of measurements performed. The mean ± SEM cerebral blood flow
in the good outcome group was 87 ± 9.5 ml/lOOg/min compared with 107 ± 11.4
ml/lOOg/min in the poor outcome group (p=0.250). Similarly, the arterio-jugular
venous difference for oxygen in the good outcome group was 5.44 ± 0.44 ml/dl
compared with 5.06 ± 0.33 ml/dl in the poor outcome group (p=0.524). The mean
cerebral perfusion pressure was higher in the good outcome group (86.5 +3.6
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mmHg) than in the poor outcome group (78.9 ± 2.6 mmHg), but this did not achieve
statistical significance (p=0.098).
DISCUSSION
The aim of this study was to investigate the adequacy of cerebral
haemodynamics in patients with an acute brain injury treated with controlled
hypertension. With this approach cerebral perfusion pressure is maintained greater
than 70 mmHg, with an arterial pressure orientated approach rather than intracranial
pressure treatment directly166. A feature of the study was simultaneous determinations
of cerebral blood flow and arterio-jugular venous difference for oxygen, to determine
the adequacy of cerebral blood flow in relation to metabolic requirement.
Methodological considerations
The nitrous oxide saturation method accurately measures global cerebral
blood flow174, but is unable to detect regional abnormalities of cerebral blood flow
that may co-exist in the presence of a normal global cerebral blood flow. However,
generalized cerebral blood flow changes have been observed to be superimposed on
lesser regional differences by other authors, in both traumatic brain injury and stroke
i8o i8i
jn t^ese S{U(jjes Xenon133 cerebral blood flow measurement techniques were
used. This allowed the authors to determine that regional and hemispheric differences
were of a lesser magnitude than global cerebral blood flow changes.
Ill
The Scheinberg modification of the original Kety-Schmidt technique was used
in our study. The main difference is the continuous collection of integrated samples
over ten minutes instead of drawing ten separate simultaneous samples from the
artery and jugular vein. This method is simpler and equally accurate175. Diffusion
equilibrium between the arterial supply, cerebral tissue and venous nitrous oxide
concentration was reached in ten minutes. We considered that the mean difference
between the two samples of 4.25% (Table 3.5) was acceptable for a biological
measurement and was in accordance with Kety's description of the methodology of
cerebral blood flow measurement.
One may question whether ten minutes was sufficient time to achieve
complete equilibration of nitrous oxide between the brain and its arterial supply. Kety
suggested that if the cerebral blood flow was normal, a study time of ten minutes
could result in a 5% overestimation of flow, but if the flow to the white matter was
reduced by one half, the overestimation increased to 10 - 12%182. However, there is
also a risk of underestimating cerebral blood flow by approximately 10%, which
relates to the admixture of blood drained from extracranial tissues (the orbital tissue
and meninges) and to the slow equilibration of the cerebrospinal fluid with nitrous
oxide. Therefore the original nitrous oxide wash-in technique is probably subject to
two relatively small errors which are in opposite directions and similar in magnitude.
Extending the equilibration time does not necessarily improve the accuracy of the
measurement. We found only once that ten minutes was not sufficient time to reach
equilibrium (arterio-jugular venous difference for nitrous oxide was greater than
10%) - this measurement was not included in our statistical analysis.
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Table 3.5 - Degree of agreement of nitrous oxide measurements. Data are expressed
as mean ± SEM.
Sample Nitrous oxide concentration
FA 188.5 ±5.6 (ppm)
FV 180.5 + 5.5 (ppm)
difference (FA - FV) 4.2 ± 0,4 (%)
Abbreviations:
FA = final arterial sample
FV = final venous sample
ppm = parts per million
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Cerebral perfusion pressure management and related physiological variables
In our patient population we used a protocol to maintain a cerebral perfusion
pressure greater than 70 mmHg, in order to protect the brain from periods of
decreased oxygen delivery as a result of arterial hypotension or intracranial
hypertension causing a compromised cerebral perfusion pressure. If autoregulation of
cerebral blood flow is preserved, an increase in cerebral perfusion pressure within the
autoregulatory range will induce cerebral vasoconstriction, causing a decrease in
cerebral blood volume and consequently a decrease in intracranial pressure. This
mechanism is known as the "vasoconstriction cascade"566. We did not assess
autoregulation in each patient, but when an increase in intracranial pressure resulted
in a reduced cerebral perfusion pressure, the mean arterial pressure was actively
increased; this manoeuvre usually caused a reduction in intracranial pressure. To
facilitate this increase in mean arterial pressure, euvolaemia was established, then a
vasoactive drug infusion (adrenaline, methoxamine or more recently noradrenaline)
was started. As a result of this protocol most of the patients had a cerebral perfusion
pressure greater than 70 mmHg during the study period.
A interesting finding of this study was the relationship between cerebral blood
flow and cerebrovascular resistance, which was described by an exponential equation
(Figure 3.3). As cerebrovascular resistance is a parameter calculated from cerebral
blood flow, we verified that this relationship was not solely due to "mathematical
coupling" by examining the relationship between arterio-jugular venous difference for
oxygen and cerebrovascular resistance (both of these variables were measured or
calculated independently, Figure 3.5). This showed a positive correlation, indicating
that there was indeed a true negative correlation between cerebral blood flow and
cerebrovascular resistance. This supports similar findings by Cruz et al.183. Under
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Figure 3.5 - Arterio-jugular difference for oxygen (AVD02) plotted against
cerebrovascular resistance (CVR). All measurements are shown as solid squares.
(r2 = 0.17, p<0.001)
physiological conditions, the relationship between cerebral blood flow and
cerebrovascular resistance should reflect changes in the activity of vascular smooth
muscle. For example if the cerebral perfusion pressure is increased within the
autoregulatory range, cerebral blood flow should remain constant, as cerebrovascular
resistance should rise. In Figure 3.3 (left-side, closed diamonds), this relationship is
absent and the vascular bed behaves passively. This behaviour has been described
previously after experimental concussive brain injury184 and after maximal relaxation
of vascular muscle with arterial hypercapnia185. In our data-set, the injury may explain
the "passive" behaviour of the vascular bed in measurements classified as hyperaemic.
Incidence and significance of hyperaemia
44% of measurements carried out were classified as hyperaemic. Using our
categorization for patients, 33% had at least one episode of hyperaemia documented.
In a similar population of comatose patients with a traumatic brain injury, Obrist et
al.155 reported at least one incidence of hyperaemia in 55% of patients. Obrist defined
hyperaemia with cerebral blood flow measurement criteria (confirmed by arterio-
jugular venous difference for oxygen). We defined hyperaemia using the arterio-
jugular venous difference for oxygen (< 4 ml/dl), as this highlights the mismatch
between oxygen delivery and oxygen demand - in effect a "relative" hyperaemia. This
difference in classification may explain the lower incidence of hyperaemia in our
population. Our study certainly supports the existence of the "luxury perfusion
syndrome" as we have clearly demonstrated cerebral blood flow in excess of
metabolic demand.
In the hyperaemic measurement group oxygen extraction was lower than in
the non-hyperaemic measurement group, at a similar vascular tone (Figure 3 .4); ie the
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cerebral metabolic rate for oxygen was lower. This signifies that coupling between
blood flow and metabolism persisted and differs from Obrist's study in which there
was no relationship between cerebral blood flow and metabolism in hyperaemic
patients155. There are several possible reasons for this discrepancy. Firstly, we used a
different technique to measure cerebral blood flow: Cook et al. showed that nitrous
oxide and Xenon methods cannot be directly compared186. Consequently, the cerebral
blood flow ranges are different. Secondly, we used a different definition for
hyperaemia and fewer patients were classified as hyperaemic. Finally, clinical
management was not extensively described in Obrist's paper155: it is likely to have
been substantially different from that of our patients, who, treated with controlled
hypertension, probably maintained a higher vascular tone that may have partially
restored the "vasoparalysis" described by Obrist.
Transcranial Doppler to define hyperaemia
The mean flow velocity was at the upper limit of the reference range in both
the hyperaemic and non-hyperaemic measurements (Table 3.3), which is similar to the
results reported by Chan et al.178, but there was no difference in mean flow velocity
between hyperaemic and non-hyperaemic measurement groups. This is not surprising
as Chan et al. suggested that the most useful diagnostic parameter for hyperaemia in
patients with traumatic brain injury was the absence of the notch in the diastolic
component of the Doppler waveform.
Outcome
Outcome results in such a small study population must be viewed with
caution, however it was of interest that the cerebral perfusion pressure was marginally
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higher in those who progressed to a good neurological outcome than those who had
an unfavourable outcome. The non-significant differences seen between hyperaemic
and non-hyperaemic patients with respect to outcome should be confirmed in a larger
study. A further study should also examine the effects of administration of a
vasopressor on outcome. We were unable to analyse this as some patients had
vasopressor administered during some measurements, but not others.
Implications for patient management
Our results show that by adopting a management protocol which includes the
use of controlled hypertension we are likely to attain an adequate cerebral blood flow
and avoid episodes of global brain ischaemia, together with maintaining coupling of
cerebral blood flow and metabolism. This approach is also less likely to result in
compromised perfusion of other organs than management which focuses solely on
treatment of intracranial hypertension with diuretics. In addition, the use of
vasopressors did not increase the incidence of hyperaemia reported by other
investigators155, who studied patients who were not receiving such drugs.
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While the use of "controlled hypertension" is a relatively simple and
inexpensive treatment regime, intensive care units are now being encouraged to
purchase and use new technology which forms part of a growing range of
sophisticated cerebral monitoring equipment now on the market. Some sources, both
commercial and scientific, claim that these monitoring devices are likely to reduce the
occurrence of secondary insults to the injured brain, and hence improve patient
outcome.
We have already discussed the use of jugular venous catheters in Chapters 2
and 3. These may also be used to monitor jugular venous haemoglobin oxygen
saturation. Another method of assessing cerebral oxygenation is near-infrared
spectroscopy, a non-invasive technique which is becoming more popular in the
intensive care unit.
In Chapter 4 we assess two different monitoring systems.
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Near-infrared spectroscopy has been used for many years in neonatal intensive
care for the study of intracerebral oxygenation and haemodynamics187"189, and such
monitors are now increasingly used in adult intensive care units and in the operating
theatre.
Near infra-red light, in the wavelength region of 700-1000 nm, is poorly
absorbed by biological tissue, however oxygen-dependent absorption spectra have
been identified in this range for three chromophores: haemoglobin (Hb), oxy-
haemoglobin (Hb02), and cytochrome aa3, the terminal enzyme in the intra-
mitochondrial respiratory chain190. This absorption is in a manner consistent with the
Beer-Lambert law for solutes:
OD = log (Io/I)-aCl
where OD, is the optical density, Io/I is the ratio of the relative intensities of incident
and transmitted light, a is the absorption coefficient, C is concentration and 1 is the
optical pathlength. Jobsis first reported the use of these principles in 1977191, when he
investigated the potential of near infra-red spectroscopy for non-invasive monitoring
of tissue oxygenation. He transmitted light through animals' heads, and provided in
vivo monitoring of changes in the oxygenation of chromophores in cerebral tissue,
describing this as a "biological window" into the brain. At least three wavelengths of
near-infrared light need to be used to accurately identify the contributions of the three
major chromophores, because the absorption spectra of Hb, Hb02 and cytochrome
aa3 are broad and overlap extensively192. The pathlength of light through brain tissue
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cannot be measured accurately in vivo, but investigators have estimated it to be
around four times the actual distance between the light source and the photodetector.
Wray et al. developed empirically derived absorption and scattering coefficients193,
and it has subsequently become possible to produce quantifiable estimations of the
percentage concentration of each chromophore by using specific algorithms.
The transmission method is inapplicable in adults because of skull density, but
the development of reflectance photometry has solved this problem. As most of the
attenuation of near infra-red light in brain tissue is by scattering rather than
absorption, light will penetrate a variable degree into the head and be reflected back.
The greater the distance from the source to the reflected component, the deeper
photons will penetrate. Rather than transilluminating the head, light travels through a
banana shaped wedge of tissue. If a second receptor is placed between the emitter and
the first receptor, it is possible to correct for the contribution of skin and bone to the
derived measurements. The propagation of light in tissues has been mathematically
modelled in a variety of ways, ranging from finite element analysis to the "Monte
Carlo" or random walk model194, which offers a better assessment of the anisotropic
component of photon diffusion. The potential clinical value of such a noninvasive
technique for early detection of cerebral hypoxia, for example intra-operatively or
after head injury, has led to the development of several models of adult cerebral
oximeters using near infra-red spectroscopy. These can be classified by the type of
light source used, ie diffuse or coherent (laser). One of the first was developed by the
Hammamatsu Corporation, which used a coherent light source and an array of
photomultiplier receptors. It is expensive, difficult to use and demands careful
application and removal of extraneous light interference by covering the head. It
provides quantifiable measurements and trending of oxy- and deoxyhaemoglobin as
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well as the redox state of cytochrome aa3. Two more recently introduced, simpler
monitoring systems, the Invos 3100 (Somanetics Corporation, USA)195 and the
Critikon 2020 (Johnson & Johnson Medical, UK) are compared in this study. The
former uses a diffuse light source with two photoreceptors contained in a single
disposable rubber adhesive patch. The receptors are spaced for subtraction of the
subcutaneous signal. It uses an algorithm that eliminates dependence upon the optical
pathlength distance. Analysis is made of the content ratios - the relative contribution
from oxygenated and deoxygenated haemoglobin. This is dependent upon an
assumption of the normal distribution of Hb and Hb02 in the brain, which is related to
the relative volumes of the arterial, venous and capillary circulations. This has been
estimated at 70% arterial, 25% venous and 5% capillary, although some researchers
have expressed reservations as to the accuracy of this. The end result is a regional
haemoglobin oxygen saturation expressed as a percentage, the rS02. Early work
revealed a positive correlation with Sj02, and McCormick et al. confirmed that the
monitor was able to discriminate between extra- and intracranial circulations with
selective perfusion techniques using Indocyananine Green196. The Critikon 2020 uses a
coherent light source and algorithms which permit quantification of the chromophores
Hb, Hb02 and cytochrome aa3. It has a large, multi-colour display screen and "user-
friendly" menu type controls. The sensor is re-usable and is attached to the forehead
of the subject with an adhesive pad.
All these monitors may be affected by the presence of extracerebral
haematomas and diffuse subarachnoid bleeding, and the validity of measurements in
patients with traumatic brain injury requires careful appraisal. Scalp haematomas may
also affect readings by altering scalp thickness and hence the photon pathways of the
Somanetics and Critikon machines, and so sensor position is important. This effect
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has been used to positive ends by the development of apparatus which identifies sites
of intracranial haematomas with a movable probe and receptors197.
In this prospective study, we aimed to compare the performance of the
Somanetics 3100 and the Critikon 2020 monitors. The systems were compared in
terms of their ability to provide a stable measurement of rS02, the variability of that
measurement and the agreement between measurements provided by the two
monitors, in resting volunteers.
METHODS
Local Ethics Committee approval was obtained in advance. Eighteen healthy
volunteers, eight female and ten male, aged between twenty one and thirty years
(mean age twenty seven years) were recruited into the study. All gave informed
consent to participate. Subjects were seated comfortably and were requested that
movement be kept to a minimum during the recording period.
The Somanetics disposable adhesive sensor and the Critikon reusable sensor
with disposable adhesive fixation pad were applied to either side of the forehead in
accordance with the manufacturers' instructions. The placement sites were free of hair
and situated as far above the supraorbital ridge and away from the midline as possible
to minimise signal interference from underlying air or venous sinuses. The skin was
cleaned and degreased prior to sensor application. A headband supplied by Critikon
secured both sensors.
The signals from the oximeters were allowed to stabilise before data collection
commenced. The protocol was divided into two stages. The sensors were applied and
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steady-state rS02 was monitored for at least 30 minutes. At the end of this period the
subject was asked to hyperventilate until they experienced a subjective sensation of
light-headedness, at which point they should return to their usual breathing pattern.
Note was taken of the time of onset and termination of hyperventilation. The sensors
were then resited so that each was placed contra-lateral to its original position and the
above procedure was repeated. Although the Somanetics sensor is not designed to be
reused, its adhesive properties were adequate for this single change in position. Data
from both oximeters were logged at intervals of 15 seconds to a personal computer
interfaced to the monitors.
Comparisons were made firstly of each monitor's practical ability to provide
stable readings of rS02 and of their relative performance in male and female subjects.
Mean rS02 values were calculated for each oximeter for the first 30 minutes of
recording. These values were used in a method comparison analysis198 to assess the
agreement (a) between oximeters running simultaneously, and (b) within oximeters
sequentially left and right. The mean change in signal observed during
hyperventilation was analysed using the same methods in order to compare size and
direction of the change in rS02 reported. When the bias between paired oximeter
readings was not constant over the range of values observed, a correlated regression
model was fitted to the bias using the generalised estimating equation (GEE)
approach199. All analysis was carried out using Splus for Windows 3.2, and the GEE




Ten of the eighteen volunteers participating in the study were successfully
monitored for the full hour (eight women, two men, mean age 23 years). In one
subject both systems recorded adequately for the first half hour but on relocation of
the sensors the Critikon failed to continue monitoring acceptable values. In two cases
the Invos performed well, while the Critikon reported a poor or absent signal; in
another two, neither oximeter was able to provide reliable readings. Three subjects
were abandoned on the basis of Critikon signal problems without assessing the
reliability of the Invos measurement. Thus, failure to obtain a stable reading occurred
in eight out of eighteen (44%) attempts with the Critikon and in two out of fifteen
(13%) with the Invos. The latter was found to work in two instances where the
former failed but there were no comparable cases where the Critikon monitored
successfully while the Invos did not. In all cases where one or both oximeters were
unable to record adequately, the subjects were male; the Critikon showed a
significantly higher failure rate in the male participants (Table 4.1, Fisher's exact test,
p=0.001).
A total of 10.5 hours of data were recorded simultaneously by both monitors
from 11 subjects (Table 4.2). A plot of the difference between the oximeter readings
against their average value (Figure 4.1) shows a clear trend for the bias to change
with the underlying value of rS02. For rS02 values in the lower range the Critikon
tended to read 5 - 10% higher than the Invos, with the reverse true at high
saturations. To explore possible causes of this phenomenon a GEE regression model
was fitted, which takes account of the fact that we have two correlated measurements
from each subject. There was no significant effect upon the bias of either the order of
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Table 4.1 - Ability of Critikon 2020 to successfully monitor cerebral oxygen
saturation
Critikon successful in monitoring?
Subjects Yes No Total
Female 8 0 8
Male 2 8 10
Total 10 8 18
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Table 4.2- A comparison of baseline readings reported
Mean rS02 *at steady state (%)
Critikon Invos
Range 64.0-71.3 56.7- 75.3
Mean 68.0 64.3
Standard Deviation 2.1 6.1
* = regional cerebral oxygen saturation
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Figure 4.1 - Differences between the regional cerebral oxygen saturation (*rS02)
shown by the Critikon and Invos monitors, plotted against their average, for each 30
minute period. The letters A to K represent individual subjects.
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measurement (first 30 minutes versus second 30 minutes, p=0.657) or the location of
the oximeters (Critikon left versus Critikon right, p=0.436), but there was a highly
significant relationship between the bias and the average rS02 (slope=-1.22,
p<0.001). The fitted regression line is plotted on Figure 4.1, and shows that from the
point of agreement at an rS02 of approximately 69%, for each percentage point
decrease in rS02, we predict the difference between the monitors to increase by
1.22%. The estimated correlation between differences observed within the same
subject was 0.133.
For the within-monitor comparisons, there was no apparent relationship
between the side-to-side differences and the average value. The observed bias (right -
left) for each monitor was not significantly different from zero (Critikon, mean = -
0.01, p=0.985 ; Invos, mean = 2.08, p=0.113). The Invos however, did show
significantly more variability (F-test for homogeneity, p=0.012), and this is reflected in
the limits of agreement, which are (-3.3, 3.3) for the Critikon and (-6.1, 10.2) for the
Invos (Figure 4.2).
For the hyperventilation phase of the experiment observed changes in rS02
ranged from -4.0% to +1.2% for the Critikon and from -9% to +1% for the Invos.
Once again the size of the disagreement between monitors was related to the size of
the change ; the larger the average decrease in rS02, the larger the difference between
monitors. A GEE regression model estimates the point of agreement at approximately
-1% and predicts that for every 1% drop in rS02 the difference between the monitors
(Critikon - Invos) will increase by 1.5% (p<0.001).
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Figure 4.2 - Differences between the average regional cerebral oxygen saturation
(*rS02) shown by each monitor for each 30 minute monitoring period, plotted against
their average for the total 60 minutes.










Much controversy surrounds the validity of rS02 measurements obtained by
reflectance cerebral near-infrared spectroscopy200"202. The original technique requires
transillumination of the neonatal skull, where determination of the optical pathlength
(the distance travelled by the photons from emitter to detector) is easily measured.
This is not the case in adults, where the use of reflectance spectroscopy means that
optical pathlength can only be estimated using complex modelling techniques. The use
of a coherent light source, with greater penetrance and less scatter, has theoretical
advantages when using these models. In this manner the Critikon 2020, using laser
optodes, should be superior to the Invos 3100 which uses a diffuse light source. A
further and important difference between the two monitors is the choice of algorithm
for quantification of rS02. The Critikon uses simultaneous solution of matrix
equations of all chromophore absorption, whereas the Invos relies upon a
questionable assumption of the compartmentalisation of the cerebral vascular bed.
Our original intention was to conduct this study on ventilated patients in the
intensive care unit and was motivated by several factors. Firstly, this technology has
been developed for clinical settings such as intensive care where cerebral oxygenation
is likely to become compromised and should therefore be assessed within that
environment. Secondly, working with this population would have allowed a much
longer total monitoring time per subject and minimised the effect of movement
artifact, shown to influence near infra-red spectroscopy signals203. Finally, we intended
to manipulate arterial oxygen saturation and partial pressure of carbon dioxide and
correlate these changes with any alteration in rS02 reported by each of the oximeters.
The insurmountable signal problems experienced with the Critikon instrument forced
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a radical revision of the original protocol to be made. It failed to register an adequate
signal from any of the four intensive care unit patients to whom it was applied, whilst
simultaneous monitoring by the Invos instrument appeared to be consistent and stable.
The decision to use healthy subjects was based on the finding that acceptable Critikon
readings were only obtainable from this group.
Our results in volunteers demonstrated a higher failure rate with the Critikon
in comparison to the Invos. Although the Invos performed poorly in two cases, the
Critikon also failed to record. It can be concluded that the Invos system is the more
likely of the two to provide a recording that is continuous and stable. The incessant
and frustrating 'poor signal' alarm that we experienced with the Critikon is totally
unacceptable in a clinical environment.
We observed a strong positive association between failure of the Critikon
monitor and male sex. Anatomical features of the head, for example skull thickness
and mass of overlying muscle, are known to vary considerably between individuals
and between different cranial regions204 205 which supports the theory that the extent of
infrared light scattering also shows inter and intra-subject variability206. Adult women
tend to have smaller, lighter and thinner skulls than men205; the existence of special
features including the prominence of the supraorbital ridges and the contours of the
forehead which can be used to distinguish between male and female crania20 is of
particular relevance to the present findings. Further support for the observed sex
difference is drawn from the suggestion that the amount of light collected by near
infra-red spectroscopy at a fixed space is greater for women than for men206.
Assuming that a similar rS02 can be expected in equivalent areas of the two
hemispheres in a healthy person, the side-to-side comparisons show that the Critikon
monitor, despite the high failure rate, does appear to have significantly less inherent
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variability than the Invos. However, the dependence of the disagreement between the
monitors upon the underlying value of rS02 suggests that either one or both of these
machines is not giving a quantified value for regional cerebral oxygen saturation. A
difference of up to 10% for values of rS02 in the range given by healthy volunteers
does not bode well for clinical application of these monitors.
The values of rS02 from both monitors decreased during hyperventilation, as
was expected because systemic hypocapnia is known to result in cerebral
vasoconstriction. Again the disagreement between the monitors varied with the
average value, providing further evidence of the uncertainty of these values of rS02.
However, without objective assessment of the change in arterial blood gas tensions it
is difficult to analyse the significance of these changes. In the majority of cases the
Invos showed the greater mean decrease in rS02, a finding that differs from a
previous report in which it failed to respond to an episode of hypercapnia201. That
study produced more detailed and direct measurements and it therefore seems
plausible that the limitations of the present study design may be responsible for any
discrepancies.
It is generally accepted that reflectance spectroscopy will become useful as a
monitor of tissue oxygenation, and signal changes attributable to variations in cerebral
oxygenation have indeed been demonstrated203 208 209 however further development is
required before this technique becomes commonly applied in intensive care. The
different algorithms used by the two systems assessed in the present study may explain
some of the lack of agreement between them. We strongly suspect that deficiencies in
sensor design may explain the unacceptably high failure rate in monitoring attributable





It is some time since Douglas Miller first proposed that "secondary insults"
such as hypotension, systemic hypoxia and hyper-pyrexia were important factors
associated with outcome after brain injury'62 '70. He suggested that it was not only the
severity of the primary injury which was important, but also the progression to
secondary injury if patient care was not optimal. His work was instrumental in the
introduction of improved intensive care of patients who had suffered a traumatic brain
injury210.
An improvement in intensive care facilities together with the development of
specialist neuro-intensive care units has, however, not brought about a dramatic
improvement in the numbers of patients who survive a severe acute brain injury with a
good neurological outcome. Graham et al. published a paper in 1989 in which
neuropathological changes of the brain were studied in patients who had died after a
traumatic brain injury163. Two time periods were studied: 1968-1972 and 1981-1982.
Despite improvements in patient management between these periods, the incidence of
ischaemic brain damage was similar in both study periods, at around 90%. Analysis of
our own secondary insult database of physiological parameters for patients with an
acute brain injury in the intensive care unit reveals a significant reduction in
hypotensive and hypoxic insults (ie periods where mean arterial pressure and arterial
haemoglobin oxygen saturation fall below acceptable limits) to the brain over a seven
year period, but this has not been paralleled by a similar reduction in mortality We
therefore must look more closely at the pathophysiology of brain injury in our
attempts to explain why this is the case.
Many "experts" have suggested that secondary injury is caused by an increase
in the local concentration of one or more biochemical substances, including the
prostaglandins, leukotrienes, superoxides of oxygen or the "excitatory" amino acids.
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Results of laboratory work have often excited researchers who have shown that
efforts to reduce local concentrations of these substances have resulted in reduced
brain tissue damage or improved functional outcome, but clinical trials in humans have
invariably been disappointing. This has particularly been the case with a class of drugs
known as the NMDA receptor antagonists (results awaiting publication).
Within the past decade there has been an increasing interest in the role of
inflammation in brain injury, and in particular the parts played by the cytokines and,
more recently, the leucocyte adhesion molecules. Our work in the field of brain
inflammation detailed in Chapter 2 showed that there is significant intracranial
production of IL-6 after injury, with jugular venous concentrations being significantly
higher than arterial. The sources of this cytokine are likely to be both glial and
haematological. At present the exact role of IL-6 in the injury process is unclear. Is
IL-6 produced as result of secondary injury mediated by other compounds eg IL-1 or
the eicosanoids, or is it produced soon after the primary injury, itself leading directly
to secondary injury?
Conversely, there is some evidence to suggest that IL-6 may in fact exert
protective effects ie it may function as an anti-inflammatory cytokine, and it may be
that the high serum concentrations seen in our work, and in the work of others,
represent attempts by the immune system to antagonise the effects of the pro¬
inflammatory cytokines such as IL-1 and TNF.
In addition we found that systemic concentrations of IL-6 were also raised
well above normal. This pattern of prolonged elevation of IL-6 is seen in the systemic
inflammatory response syndrome and in the adult respiratory distress syndrome
(ARDS), and serum concentrations of IL-6 have been shown to be related to outcome
in these conditions both in terms of maximum concentrations detected211 and of
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persistence of IL-6 in serum over time212213. The increase in systemic IL-6 seen in our
study is unlikely to be the result of intracranial production only; it is likely that there is
a systemic inflammatory response after brain injury during which IL-6 is produced by
other organs and tissues. These other sources may therefore also be involved in the
intracranial inflammatory process. It would certainly be interesting to measure, for
example, transpulmonary gradients for IL-6, taking samples from central venous and
pulmonary artery catheters in patients with brain injury, and to compare these results
with transcranial gradients in each patient. This is one avenue which I may explore in
future studies.
There has been little work relating outcome in acute brain injury to IL-6
concentrations in serum. In this study we were unable to show any relationship
between these two factors, whereas there was a strong relationship between sICAM-1
concentrations and poor neurological outcome. This suggests that any attempt to
antagonise the actions of IL-6 in the clinical setting may not be helpful. There is little
if any published work which has explored antagonism of IL-6 in the laboratory, and
related this to outcome measures.
Of much greater interest is the theory that antagonism of the pro-inflammatory
cytokines IL-ip and TNFa may improve outcome in brain injured patients - but do
these cytokines play an important part in the pathophysiology of secondary brain
injury in humans? Unfortunately I was unable to show any increase in the serum
concentrations of these cytokines in my patient group. This reason for this is likely to
be that as a tertiary referral centre, we receive these patients some time after the injury
has occurred - in this study a median time of eight hours thirty minutes after injury.
The peak of production of these pro-inflammatory cytokines is probably within 2-4
hours of injury, and with a half life of not more than 30 minutes, they would have
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disappeared from the circulation before I was able to take the first serum samples.
Hence another possibility for future work is to gain earlier access to the patient to
sample systemic blood. One opportunity may be to work with neurosurgeons at the
Royal London Hospital who are involved in the Helicopter Emergency Medical
Service. Here medical staff have early access to a substantial number of patients who
have sustained a closed head injury.
I was, however, able to show a strong link between sICAM-1 concentrations
and poor neurological outcome. Upregulation of the production of adhesion
molecules occurs later than the peak activity of IL-ip and TNFa, and is therefore
more open to antagonism at the point when the patient is admitted to the intensive
care unit. The work carried out with adhesion molecule antagonists in animal stroke
models by the two American groups discussed in Chapter 1 is of great interest124"12 13°.
The next step must be to extend this work to look at rats which have sustained a
traumatic brain injury, and I believe that there is a German group which has started
such a project. The results of the phase 3 trial underway in stroke patients at present
will also be a very important pointer as to the likely success of this therapy in other
types of acute brain injury.
The fact that we were unable to show any transcranial gradient for the
adhesion molecules is perhaps a little surprising given the strong relationship between
sICAM-1 concentrations and both neurological outcome and severity of neurological
injury. One might imagine that significant upregulation of ICAM-1 production in
cerebral micro-vessels would lead to increased concentrations of sICAM-1 in jugular
venous blood. Again we must look to the fact that both local intracranial and systemic
upregulation of adhesion molecule activity is likely to be important. As I have
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discussed above with reference to IL-6, it would be interesting to examine
concentrations of adhesion molecules in blood draining other organs in the body.
Our findings of a marked reduction in serum sL-selectin contrast with the
majority of studies which have looked at this adhesion molecule in other disease
states. One important study however, published by Donnelly et al111, found a similar
reduction in sL-selectin in patients thought to be at risk of developing ARDS.
Reduced concentrations of sL-selectin in serum correlated with the development of
ARDS and poor outcome. Similarly, in Fassbender's study110, reduced serum sL-
selectin was found in stroke patients.
There is no previously published clinical work which has studied serial
concentrations of adhesion molecules in traumatic brain injury and subarachnoid
haemorrhage in either arterial or jugular venous serum, therefore my work must be
regarded as merely the first step in the investigative process. A study by Fassbender et
al.110 looked at serial changes of adhesion molecules after acute ischaemic stroke and
found a rise in sICAM-1 and a reduction in sL-selectin. Jander et al found increased
sICAM-1 in the serum of patients with bacterial meningitis106, but not other
neurological diseases, such as multiple sclerosis and the Guillan-Barre syndrome
Measurement of systemic sICAM-1 concentrations may be helpful in
prediction of those cases which should do well, and those which are likely to die or do
badly. Although it would be impossible to make a prediction of neurological outcome
with any degree of certainty, the assay may be able to assist clinicians in decision
making, particularly if repeated over the first 2 days of admission. The development of
microdialysis catheters which allow frequent sampling of brain tissue fluid may also
allow our research group to improve our knowledge of the time course of
inflammatory mediators in brain tissue itself. Further laboratory work must also
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include immunohistochemical analysis of brain tissue specimens, both from "live"
brain taken during craniotomy and from post-mortem specimens, to examine adhesion
molecule activity in micro-vessels and brain tissue.
My work has also given further support to the theory that both S-100 and
NSE are useful markers of brain injury. Measurement of these compounds in serum
may also help to predict outcome in individual cases. Microdialysis may in future offer
a suitable vehicle for ongoing frequent analysis of these molecules, which may give
the intensivist additional information to aid further management.
Much of the work summarised in chapter 2 deals with the future, whereas the
novel therapy discussed in Chapter 3 is happening now in many intensive care units
across the world, without any randomised controlled trials having been carried out to
suggest that it improves outcome. Whilst many, led by Michael Rosner166, believe that
induced hypertension should be part of "standard" management for patients with
traumatic brain injury, there is another body of opinion which advocates the opposite!
A very different approach is adopted by others, led by "the Lund group" from
Sweden214"216. They argue that to avoid cerebral oedema, patients with traumatic brain
injury should be treated with cerebral vasoconstrictors and hypotensive agents. Both
groups claim to have similarly good outcome figures, but the studies are small and are
certainly not controlled studies of one treatment versus the other. The majority of
intensivists agree with the Rosner approach, but some believe that in some cases
where cerebral autoregulation is deficient, induced hypertension may cause
intracranial hypertension and therefore worsen cerebral ischaemia.
In Chapter 3 we showed that every measurement of cerebral blood flow made
in our patient group was either within or above the normal range. Global cerebral
hypoperfusion was therefore not detected during our study. There is therefore a
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discrepancy between our results and the common finding at post-mortem of ischaemic
brain damage in fatal traumatic brain injury as discussed at the start of this chapter163.
Possible explanations include the effects of our clinical management or the
limitations of the cerebral blood flow measurement technique. All the methods based
on the Fick principle express cerebral blood flow in terms of ml/lOOg of brain tissue
perfused per minute. If there are areas which are not perfused, they will not be
included in the calculation. Therefore, even in the absence of global ischaemia, there
may be areas of the brain where blood flow is reduced to critical levels and which may
co-exist with areas of hyperaemia. Heterogeneity of cerebral blood flow cannot be
measured by arterio-jugular venous differences across the whole brain. Another
possibility is that global cerebral hypoperfusion was not detected because cerebral
blood flow was measured only when the cerebral perfusion pressure was stable, but
this method was employed to avoid interfering with the clinical management of
patients and to obtain reliable cerebral blood flow measures.
Many researchers have suggested that cerebral ischaemia, if present, occurs
early after injury and may have resolved by the time cerebral blood flow is measured
in the intensive care unit. Our measurements were all performed several hours or days
after the injury, and it may be that we missed periods where cerebral blood flow was
compromised. Bouma et al. reported that periods of low blood flow were common in
the first few hours after injury - a cerebral blood flow below the threshold for
infarction (18 ml/lOOg/min) was present in 30% of measurements obtained within the
first 6 hours after trauma - and that flow rapidly increased in subsequent
measurements217. They also found that periods of low cerebral blood flow which
occurred at more than 24 hours after injury were associated with a low arterio-jugular
venous difference for oxygen, suggesting a low cerebral metabolic rate rather than
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frank ischaemia. In our study we showed that in many cases, cerebral blood flow was
in excess of metabolic requirements (hyperaemia) and that arterio-jugular difference
for oxygen was reduced. It may therefore be that, as all our measurements were
carried out at least 6 hours after brain injury, we missed periods of reduced cerebral
blood flow, in a fashion similar to our missing the peak production of the cytokines
IL-ip and TNFa.
The absence of global ischaemia by blood flow criteria is backed up in our
study by the absence of any ischaemia both by arterio-jugular difference for oxygen
and lactate oxygen index criteria. Taken together these results form a convincing
argument against the theory that, as autoregulation is often absent in those who have
sustained a traumatic brain injury, induced hypertension will often result in cerebral
ischaemia. Indeed it is also interesting to note that the average mean arterial pressure
was actually higher in the group of patients who had had no episodes of hyperaemia
noted at all.
What do these results mean in practical terms? Obviously without a properly
conducted randomised controlled trial into hypertension / normotension / hypotension
as a mainstay of treatment for traumatic brain injury, I am unable to advocate one
method with any authority. It is now unlikely that such a trial will ever be carried out,
as many would find it unethical to treat patients in a "hypotensive" group in such a
study. This is a good example of a problem which has been highlighted by one of the
statisticians (David Signorini) working in brain injury at several international meetings
recently - that is the lack of any good Class 1 evidence to support many of the
treatment and monitoring practices currently employed by those neurosurgeons and
intensivists managing patients who have sustained an acute brain injury.
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My study, however, suggests that complications resulting from the use of
induced hypertension are unlikely, and that it is not a dangerous therapeutic approach.
Indeed it is now almost universally employed in the management of spontaneous
subarachnoid haemorrhage, and I believe will in future become part of standard
management in traumatic brain injury.
The use of controlled hypertension to increase cerebral perfusion pressure is
directed towards maintaining or increasing oxygen delivery to brain tissue.
Technological developments in monitoring of cerebral oxygenation mean that
continuous jugular venous haemoglobin oxygen saturation monitoring is employed in
many neuro-intensive care units - indeed it is standard practice in our unit in
Edinburgh. This means that periods during which arterio-jugular venous oxygen
content difference is increased - suggesting that oxygen delivery to the injured brain is
inadequate - are now less common and less prolonged, as they are treated
immediately. Invasive probes which monitor the partial pressure of oxygen in brain
tissue directly are now in clinical use218"220. Again these can provide an early indication
that oxygen delivery to brain tissue is inadequate.
As I have discussed in Chapter 4, near-infrared spectroscopy is likely to be an
important monitoring technique in the future. It is non invasive and therefore easily
applied in all intensive care units, particularly in those outwith neurosurgical centres.
There will of course be those who feel that the "explosion" in monitoring technology
is perhaps of more benefit to the companies which manufacture these often hugely
expensive items of equipment, than to patients (I showed in Chapter 4 that the
Critikon 2020 was in effect useless in the intensive care unit). Again ideally we should
carry out large randomised controlled trials which would firmly establish whether an
item of monitoring resulted in improved outcome. Practically of course this is just not
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possible. There would be the ethical problem of treating patients without monitoring
that some would regard as essential. There would also be the problem of standardising
treatment so that outcome would not be biased by other differences in management.
At present the near infrared spectroscopy monitors are inadequate for routine
use on patients -with brain injury, but it will not be long before the technical difficulties
experienced so far are overcome, and despite the reservations of some intensivists,
they are commonly used in both the operating theatre and intensive care unit to
monitor cerebral oxygenation.
Finally I need to bring my ideas together. I have mentioned the improved
monitoring now available, and at a novel therapy which is now routine in our intensive
care unit, however if I again look back at Chapter 3 and examine our outcome figures
it is apparent that neurological outcome was disappointing with only nine out of
twenty nine patients having a good outcome. These figures are not atypical for a
similar group of patients in other neurointensive care units.
As a result of improvements in management and monitoring, oxygen delivery
to the brain, except perhaps during short periods soon after injury, is likely to be
maintained in the intensive care environment, in the absence of uncontrollable
intracranial hypertension. This therefore raises a fundamental question that can lead to
much speculative discussion: why if oxygen delivery to the injured brain is equal to,
or in many cases well above the metabolic requirements of the brain, do we see
ischaemic brain damage so frequently after brain injury?
I believe that we must look to failure of cellular oxygen consumption as a
possible cause of ischaemic cell damage, ie a state of histotoxic hypoxia exists. This is
not a new suggestion. As long ago as the mid 1980s workers such as Yang et al.221
and Vink et al.222 proposed that traumatic brain injury resulted in an impairment of
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brain mitochondrial respiratory chain function, which meant that oxygen delivered to
brain tissue could not be used for aerobic metabolism. There is substantial evidence
from experimental work that mitochondrial function is abnormal in animal models of
cerebral ischaemia223 224, and in some studies these abnormalities appear to worsen as
time progresses224. Poor neurological outcome has also been correlated with persisting
abnormalities of mitochondrial function224 225.
We can therefore speculate that in certain inflammatory disease states,
production of pro-inflammatory mediators may prevent cells from utilising the oxygen
supplied to tissues. This may explain, for example, why therapeutic efforts directed at
increasing oxygen delivery to tissues have not resulted in improved outcome in the
systemic inflammatory response syndrome.226 227. After an initial primary cerebral
injury, with transient ischaemia followed by reperfusion, an inflammatory response is
initiated. Mediators such as the cytokines, arachidonic acid metabolites and oxygen
free-radicals cause microvascular dysfunction, with plugging of small vessels by
platelets and neutrophils, and migration of neutrophils into brain tissue. This is
associated with mitochondrial calcium overload with a reduction in their respiratory
capacity228 229. The worsening of mitochondrial function with time may be associated
with a gradual increase in the activity of pro-inflammatory mediators, such as ICAM-
1, in patients who go on to a poor neurological outcome.
There would appear to be no direct chain of events which can be easily broken
at one point, but a complex web of inter-related processes and mediators which
ultimately leads to cell death. To improve outcome after acute brain injury we need to
prevent the processes which lead to cell death from occurring. Improved monitoring
techniques and careful attention to the metabolic requirements of the brain whilst in
the intensive care unit are important, but new drug therapies which antagonise the
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effects of the inflammatory process after brain injury may, in the future, prove to be a
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Transcranial cytokine gradients in patients requiring intensive care
after acute brain injury
E. G. McKeating, P. J. D. Andrews, D. F. Signorint and L. Mascia
Summary
After acute brain injury there may be increased
intracranial production of cytokines, with activa¬
tion of inflammatory cascades. We have sought to
determine if a transcranial cytokine gradient was
demonstrable in paired sera of 32 patients requir¬
ing intensive care after acute brain injury. The dif¬
ference between concentrations of IL-1f3, IL-6, IL-8
and TNFa in jugular venous and arterial serum was
measured on admission, and at 24, 48 and 96 h
after the primary injury. There were no differences
in IL-ip, IL-8 or TNFa, but median gradients of 6.7
and 11.5 pg ml-1 for IL-6 were demonstrated in the
traumatic brain injury (n= 22) and subarachnoid
haemorrhage (n=10) groups, respectively (normal
values in serum <4.7 pg ml-1; P<0.001 both
groups). This suggests that there is significant pro¬
duction of IL-6 by intracranial cells after acute brain
injury. Therapy directed towards combatting the
negative effects of IL-6 may potentially benefit
patients who have sustained an acute brain injury.
(Sr. J. Anaesth. 1997; 78: 520-523).
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The cytokines are a variety of polypeptide molecules
which function as mediators within the communica¬
tion network of the immune system.1 They have
been implicated in the pathophysiology of many
disease processes, including the systemic inflamma¬
tory response syndrome (SIRS),2 acute respiratory
distress syndrome (ARDS)3 and multiple trauma.4
Many of the biological effects of the cytokines are
clinically evident after acute brain injury; these
include neutrophilia, pyrexia and alteration of
endothelial permeability,5 which may result in
cerebral oedema,6 as a result of disruption of blood-
brain barrier function.
Increased concentrations of serum tumour necrosis
factor-a (TNFa),7 interleukin-6 (1L-6)8 and intraven¬
tricular fluid IL-6 and IL-1(39 have been demon¬
strated after traumatic brain injury, and experimental
work has demonstrated that glial cells are able to
manufacture cytokines.1011 After acute brain injury it
has been suggested that increased intracranial produc¬
tion of pro-inflammatory cytokines, with consequent
induction of auto-destructive inflammatory cascades,
results in secondary injury to the brain, causing
altered brain metabolism and cell death.12 With the
increased use of intra-parenchymal solid state
methods for monitoring intracranial pressure, access
to cerebrospinal fluid for analysis is often not possible,
and where it is, sampling from catheters may result in
ventriculitis.13 Insertion of a fibreoptic catheter into
the jugular bulb to monitor jugular venous haemo¬
globin oxygen saturation is now standard practice
within our intensive care unit (ICU) in acute brain
injured patients, giving ready access to blood draining
from the brain.14 We investigated the hypothesis that
systemic concentrations of the cytokines EL-1(3, EL-6,
EL-8 and TNFa are increased after acute brain injury,
and that increased intracranial production of these
cytokines results in a demonstrable transcranial
cytokine gradient, with jugular venous concentrations
higher than arterial concentrations.
Patients and methods
After obtaining local Ethics Committee approval, we
studied 32 patients who had sustained an acute brain
injury (traumatic brain injury (TBI) or spontaneous
subarachnoid haemorrhage (SAH)) requiring inten¬
sive care. Patient data consisting of sex, age and
Glasgow coma score (GCS) after non-surgical resus¬
citation were recorded on admission to the ICU (see
table 1). One patient whose initial GCS was
recorded as 15 was anaesthetized at the scene soon
after injury because of flail chest. Computerized
tomography (CT) subsequently demonstrated
severe traumatic brain injury.
A dual-lumen Edslab 4-French gauge oximetry
catheter (Baxter Healthcare Corporation, Irvine,
CA, USA) was inserted into the jugular bulb on the
dominant side of the cerebral venous drainage, as
described previously.1516 Satisfactory positioning
was ensured by lateral x-ray of the cervical spine
(catheter tip seen cephalad to the upper border of
the C2 vertebral body), and the correct catheter
distance marking (e.g. 15 cm) showing at the valve
of the sheath was written in the notes for future
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Table 1 Characteristics of patient population (median (range)).
The characteristics of the subset, including only the first 20
patients, are shown in parentheses
TBI group SAH group
(»=22(12)) II © 00
Sex (M/F) 18/4 (9/3) 6/4 (4/4)
Age (yr) 34 (35) 52 (51.5)
17-69 (17-49) 21-65 (21-65)
GCS 7(7) 7(7)
3-15 (3-15) 5-10 (5-10)
Table 2 Performance characteristics of each assay. To assess
intra-assay precision, three samples of known concentration were
assayed 20 times on one plate. To assess inter-assay precision,
three samples of known concentration were assayed in 20
separate assays
Intra-assay coefficient Inter-assay coefficient
of variation (%) of variation (%)
Sample 1 2 3 1 2 3
IL-1|3 3.4 4.4 2.8 8.4 4.2 4.1
IL-6 4.3 1.7 2.1 6.3 3.3 7.2
IL-8 3.9 2.4 3.3 12.2 9.1 7.3
TNFa 5.2 4.2 4.6 7.4 4.6 5.4
reference. An intra-arterial catheter was inserted (if
not already in situ), usually in the radial artery, as is
our standard practice.
Paired arterial and jugular venous blood samples
were obtained at designated times after brain injury:
within 12 h (median 8 h 30 min, range 2-14 h), and
at 24, 48 and 96 h. Time of brain injury in the SAH
group was noted as the time of sudden deterioration
in GCS by 3 points or more. Patients who did not
exhibit sudden neurological deterioration were not
included. The diagnostic criterion for SAH was the
presence of subarachnoid blood on the CT scan.
Satisfactory positioning of the jugular bulb catheter
was ensured before each sample was obtained by
checking that the correct distance marker of the
catheter was showing at the sheath valve. Samples
were allowed to clot at room temperature, spun
down in a centrifuge at 4000 rpm for 10 min and the
supernatant removed and frozen immediately at
-25°C. Analysis of serum for IL-ip, IL-6, IL-8 and
TNFa was performed by enzyme-linked
immunosorbent assay (Quantikine Human Cytokine
Assays, R&D Systems) according to the manu¬
facturer's instructions. Inter- and intra-assay coeffi¬
cients of variation for each assay are shown in table
2. All analyses were carried out by a single operator
using the same equipment and procedures through¬
out. Repeat ffeeze-thaw cycles for serum samples
were avoided by separating the serum from each
patient into four tubes before freezing.
A total of 138 samples (69 pairs) were analysed in
duplicate for each cytokine (with an additional 80
samples for IL-6) and results averaged to give the
final concentration. Samples which gave a result
higher than the highest standard supplied with the
kit were diluted and the assay repeated. Sera from
eight healthy volunteers were analysed as controls.
Standard curves and cytokine concentrations were
calculated on a personal computer interfaced to a
micro-plate reader using dedicated software (Bio-
Rad Laboratories). Statistical analysis was by
Wilcoxon rank sum and signed rank tests using
Splus for Windows 3.2.
Results
In 119 of the 138 samples assayed for IL-1(3
(86%), concentrations were undetectable (<3.9 pg
ml'1). The highest concentration in the remaining
19 (14%) was 7.0 pg ml-1. For TNFa, in 122
samples (88%) concentrations were undetectable
(<15.6 pg ml"1). The highest concentration in the
remaining 16 (12%) was 31 pg ml-1. IL-8 was
detected in 72 samples (52%) (lower limit of
detection 94 pg ml"1), but only 10 (7%) showed
concentrations >300 pg ml-1. There was no differ¬
ence between jugular venous and arterial concen¬
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Figure I Differences between jugular venous and arterial concentrations of IL-6 in traumatic brain injury (TBI,
n = 22) and spontaneous subarachnoid haemorrhage (SAH, n= 10), over a 4-day period after injury (A=admission).
Data may be incomplete because of patient death, discharge from ICU or values lying outside ELISA quantification
values. For the TBI group, at each time, n=20, 21, 19 and 11, respectively; for the SAH group, n= 10, 10, 8 and 6,
respectively.
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with detectable concentrations. Control samples
all showed undetectable concentrations.
IL-6 was detected in all 218 samples. In the con¬
trols, concentrations were below detectable limits
(<3.1 pg ml"1) in four samples. The highest con¬
centration in the remaining four control samples was
4.7 pg ml-1. In four pairs of patient samples (3.7%),
both samples showed concentrations >1500 pg ml-1
(the upper limit of quantification) and were
excluded from statistical analysis. In 82 (78.1%) of
the remaining 105 pairs, jugular venous concentra¬
tion was higher than arterial. In the TBI group,
median jugular venous concentration was 74.8
(range 19.9-539.8) pg ml"1), median arterial con¬
centration was 63.5 (11.4-518.4) pg ml-1 and the
median difference was 6.7 (—40.8 to 244.4) pg ml-1
(P<0.001). In the SAH group, median jugular
venous concentration was 64.6 (19.1-455.4) pg
ml-1, median arterial concentration was 54.1 (12.2
to 407.4) pg ml-1 and the median difference was
11.3 (-32 to 135.2) pg ml"1 (P<0.001).
Figure 1 shows the individual patient profiles for
transcranial IL-6 gradient for each group. In the TBI
group, median gradients at each time point were
19.2 (P<0.001), 10.5 (P=0.014), 6.3 (P=0.018)
and 1.6 pg ml"1 (P=0.147), respectively. In the
SAH group, median gradients were 26.8 (P= 0.002),
20.1 (P=0.027), 5.6 (P=0.383) and 7.8 pg ml"1
(P=0.094), respectively. Comparing the TBI and
SAH groups, there was a significant difference in age
between the groups (P= 0.028), but there was no
difference in GCS (P=0.979). There was no
overall difference in IL-6 gradients across the brain
between the TBI and SAH groups (P= 0.350); there
were no differences between groups at any of the
four sampling times (P=0.559, 0.627, 0.832, 0.366,
respectively).
Discussion
We were unable to derive any useful information
from measurement of either arterial or jugular
venous serum concentrations of IL-1(3, IL-8 or
TNFa at these times after acute brain injury. It is
generally believed that IL-lp and TNFa are released
in the early post-injury phase,1718 resulting in
increased synthesis of IL-6, in addition to other
mediators. IL-6 may act to decrease production of
IL-ip and TNFa via a negative feedback mecha¬
nism.19 It may be that we missed an early peak of
production of IL-1(3 and TNFa before the patients
reached the ICU. The relatively high lower limit of
detection for IL-8 (94 pg ml"1) in this particular
assay may have masked any significant transcranial
gradient.
Results for IL-6 show increased jugular venous
concentrations of this cytokine relative to arterial
concentrations, particularly within 48 h of brain
injury. Transcranial gradients in the TBI and SAH
groups were similar, despite different aetiologies of
primary injury, suggesting that the mechanisms of
the inflammatory process may be similar. The
median transcranial gradient on admission in each
group was 5-6 times higher than the highest sys¬
temic concentration measured in the controls. This
suggests significant intracranial production of IL-6.
The source of this increased production is likely to
be glial cells, and there is experimental evidence to
suggest that both astrocytes10 and microglial cells11
may be involved. In addition, systemic concentra¬
tions of IL-6 were increased greatly. This may be
caused solely by intracranial production, but is much
more likely to be a result of release of IL-6 from
extracranial sources, that is a mild SIRS. Variation in
systemic concentrations of IL-6, jugular
venous-arterial differences, and different patterns of
concentration gradients seen over time may be
related to the severity of intracranial injury, type of
injury, presence of extracranial injuries or secondary
insults to the brain while in the ICU.
This pattern of prolonged elevation of IL-6 is seen
in SIRS and ARDS, and serum concentrations of
IL-6 have been shown to be related to outcome in
these conditions, both in terms ofmaximum concen¬
trations detected20 and persistence of IL-6 in serum
over time.2122 There has been little work relating
outcome in acute brain injury to IL-6 concentrations
in serum. We are presently collecting outcome data
for our group of patients.
A study which compared post-mortem appear¬
ances of the brains of non-survivors of traumatic
brain injury in Glasgow over two periods
(1968-1972 and 1981-1982) showed that the inci¬
dence of ischaemic damage had not changed, despite
improved intensive care in this group of patients.23
Analysis of our own secondary insult database of
physiological variables for acute brain injured
patients in the ICU revealed a significant reduction
in hypotensive and hypoxic insults (i.e. periods
where mean arterial pressure and arterial haemo¬
globin oxygen saturation decreased to below accept¬
able limits) to the brain over a 7-yr period, but this
has not been parallelled by a similar reduction in
mortality. We can speculate that in inflammatory
disease states the mediators produced may prevent
cells from using oxygen supplied to tissues, that is
there exists a state of histotoxic hypoxia. This may
explain why therapeutic efforts directed at increasing
oxygen delivery to tissues have not resulted in
improved outcome in SIRS.2425 If this hypothesis
is correct then a different therapeutic approach is
necessary.
Future management of acute brain injured
patients may include pharmacological modification
of the inflammatory processes involved in the patho¬
physiology of the condition, using antibodies or
receptor antagonists, preventing further cell death
and improving outcome.
References
1. Bellanti JA, Kadlec JV, Escobar Gutierrez A. Cytokines and
the immune response. Pediatric Clinics ofNorth America 1994;
41: 597-621.
2. Damas P, Ledoux D, Nys M, Vrindts Y, De Groote D,
Franchimont P, Lamy M. Cytokine serum level during severe
sepsis in human IL-6 as a marker of severity. AnnaLs ofSurgery
1992;215:356-362.
3. Donnelly SC, Strieter RM, Kunkel SL, Walz A, Robertson
CR, Carter DC, Grant IS, Pollok AJ, Haslen C. Interleukin-
8 and development of adult respiratory distress syndrome in
at-risk patient groups. Lancet 1993; 341: 643-647.
Cytokine gradients after acute brain injury
4. Foex BA, Lamb WR, Roberts TE, Brear SG, Macartney I,
Hammer M, Brenchley PEC. Early cytokine response to
multiple injury. Injury 1993; 24: 373—376.
5. Maruo N, Morita I, Shirao M, Murota S. IL-6 increases
endothelial permeability in vitro. Endocrinology 1992; 131:
710-714.
6. Yamasaki Y, Suzuki T, Yamaya H, Matsuura N, Onodera H,
Kogure K. Possible involvement of interleukin-1 in ischemic
brain edema formation. Neuroscience Letters 1992; 142:
45-47.
7. Goodman JC, Robertson CS, Grossman RG, Naravan RK.
Elevation of tumour necrosis factor in head injury. Journal of
Xeuroimmunology 1990; 30: 213-217.
8. McClain C, Cohen D, Phillips R, Ott L, Young B. Increased
plasma and ventricular fluid interleukin-6 levels in patients
with head injury. Journal of Laboratory and Clinical Medicine
1991; 118: 225-231.
9. McClain CJ, Cohen D, Ott L, Dinarello CA, Young B.
Ventricular fluid interleukin-1 activity in patients with head
injury. Journal of Laboratory and Clinical Medicine 1987; 110:
48-54.
10. Hariri RJ, Chang VA, Barie PS, Wang RS, Sharif SF,
Ghajar JB. Traumatic injury induces interleukin-6 produc¬
tion by human astrocytes. Brain Research 1994; 636:
139-142.
11. Woodroofe MN, Sarna GS, Wadhwa M, Hayes GM,
Loughlin AJ, Tinker A, Cuzner ML. Detection of inter¬
leukin-1 and interleukin-6 in adult rat brain, following
mechanical injury, by in vivo microdialysis: evidence of a role
for microglia in cytokine production. Journal of
Xeuroimmunology 1991; 33: 227-236.
12. Ott L, McClain CJ, Gillespie M, Young B. Cytokines and
metabolic dysfunction after severe head injury. Journal of
Xeurotrauma 1994; 11: 447—472.
13. Paramore CG, Turner DA. Relative risks of ventriculostomy
infection and morbidity. Acta Xeurochirurgica 1994; 127:
79-84.
14. Lam JMK, Chan MSY, Poon WS. Cerebral venous oxygen
saturation monitoring: Is dominant jugular bulb cannulation
good enough? British Journal of Neurosurgery 1996; 10:
357-364.
15. .Andrews PJ, Dearden NM, Miller JD. Jugular bulb cannula¬
tion: description of a cannulation technique and validation of
523
a new continuous monitor. British Journal of Anaesthesia
1991;67:553-558.
16. Souter MJ, Andrews PJD. Validation of the Edslab dual
lumen oximetry catheter for continuous monitoring of
jugular bulb oxygen saturation after severe head injury.
British Journal ofAnaesthesia 1996; 76: 744-746.
17. Shohami E, Novikov M, Bass R, Yamin A, Gallily R. Closed
head injury triggers early production of TNF alpha and IL-6
by brain tissue. Journal of Cerebral Blood Flow and Metabolism
1994; 14: 615-619.
18. Taupin V, Toulmond S, Serrano A, Benavides J, Zavala F.
Increase in EL-6, IL-1 and TNF levels in rat brain following
traumatic lesion. Influence of pre- and post-traumatic treat¬
ment with Ro5 4864, a peripheral-type (p site) benzodiazepine
ligand. Journal ofXeuroimmunology 1993; 42: 177-185.
19. Hofrnan F.M, Hinton DR. Cytokine interactions in the
central nervous system. Regional Immunology 1990; 3:
268-278.
20. Patel RT, Deen KI, Youngs D, Warwick J, Keighley MRB.
Interleukin 6 is a prognostic indicator of outcome in severe
intra-abdominal sepsis. British Journal of Surgery 1994; 81:
1306-1308.
21. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ,
Dupont E. Serum cytokine levels in human septic shock;
Relation to multiple-system organ failure and mortality. Chest
1993; 103: 565-575.
22. Meduri GU, Headley S, Kohler G, Stentz F, Tolley E,
Umberger R, Leeper K. Persistent elevation of inflammatory
cytokines predicts a poor outcome in ARDS: Plasma
IL-1 beta and IL-6 levels are consistent and efficient
predictors of outcome over time. Chest 1995; 107:
1062-1073.
23. Graham DI, Ford I, Adams JH, Doyle D, Teasdale GM,
Lawrence AE, McLellan DR. Ischaemic brain damage is still
common in fatal non-missile head injury. Journal of
Neurology, Neurosurgery and Psychiatry 1989; 52: 346-350.
24. Hayes MA, Timmins AC, Yau EHS, Palazzo M, Hinds CJ,
Watson D. Elevation of systemic oxygen delivery in the treat¬
ment of critically ill patients. New England Journal ofMedicine
1994; 330: 1717-1722.
25. Ronco JJ, Fenwick JC, Tweeddale MG. Does increasing
oxygen delivery improve outcome in the critically ill? No.
Critical Care Clinics 1996; 12: 645—659.
Anaesthesia, 1997, 52, pages 136-140
APPARATUS
A comparison of the Invos 3100 and the Critikon 2020
near-infrared spectrophotometers as monitors of cerebral
oxygenation
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Summary
Assessment of cerebral oxygenation using near-infrared spectroscopy in intensive care is increasing.
We compared the ability of the Invos 3100 and the Critikon 2020 monitors to produce stable and
consistent readings of regional cerebral oxygen saturation in resting volunteers. Failure to obtain
any stable reading with the Critikon occurred in eight out of 18 subjects (44.4%) and with the
Invos in three out of 15 subjects (20%). The Critikon showed a significantly higher failure rate in
male subjects (p = 0.0011). Differences in recorded values of cerebral oxygen saturation
(Critikon — Invos) ranged from —4.7% to 12.6% and were significantly related to the average
saturation level (p <0.0001). The within-monitor variability was significantly higher for the Invos
(p = 0.0124). Neither monitor is able to give stable and consistent readings over time, particularly
in male subjects. The unacceptably high failure rate of the recently introduced Critikon 2020 will
limit or prevent its clinical use.
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Near-infrared spectroscopy (NIRS), introduced in 1977
by Jobsis [1], has been used for several years in neonatal
intensive care for the study of intracerebral oxygenation
and haemodynamics [2-4]. The technique relies upon the
relative transparency of soft biological tissues (including
the fetal skull) to radiation in the near-infrared region
(700-1000 nm) and upon the presence in tissues of chro-
mophores whose light-absorbing properties van- with
oxygenation. In cerebral tissue these chromophores are
oxyhaemoglobin, deoxyhaemoglobin and cytochrome
oxidase aa3, the terminal enzyme of the mitochondrial
respiratory chain. This transmission method is inapplicable
in adults owing to skull density, but a reflectance technique
has been developed which purports to measure absorption
in the cerebral cortex. After the application of subtraction
algorithms to remove extracranial contributions, estimates
of regional percentage haemoglobin oxygen saturation
(cerebral oxygen saturation or rso2) can be derived from
the signals.
The potential clinical values of such a noninvasive
technique for early detection of cerebral hypoxia, for
example intra-operatively or following head injury, has
led to the development of several models of adult cerebral *
oximeters using NIRS. These can be classified by the type
of light source used, i.e. diffuse or coherent (laser). The
aim of this prospective study was to compare the perfor¬
mance of two monitoring systems, the Invos 3100 (Soma-
netics Corporation, USA) [5], which uses a diffuse light
source and the more recently introduced Critikon 2020
(Johnson & Johnson Medical, UK), which uses a coherent
light source. The systems were compared in terms ot their
ability to provide a stable measure of rso2, the variability
of that measure and the agreement between measures
provided by the two monitors in resting volunteers.
Methods
Local Ethics Committee approval was obtained in
advance. Eighteen healthy volunteers, eight female and
10 male, aged between 21 and 30 years (mean age 27 years)
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were recruited into the study. All gave informed consent.
Subjects were seated comfortably and were asked to keep
movement to a minimum during the recording period.
The Somanetics disposable adhesive sensor and the
Critikon reusable sensor with disposable adhesive fixation
pad were applied to either side of the forehead in accord¬
ance with the manufacturers' instructions. The placement
sites were free of hair and situated as far above the
supraorbital ridge and away from the midline as possible
to minimise signal interference from underlying air or
venous sinuses. The skin was cleaned and degreased prior
to sensor application. A headband supplied by Critikon
secured both sensors.
The signals from the oximeters were allowed to stabilise
before starting data collection. The protocol was divided
into two stages. The sensors were applied and steady-state
cerebral oxygen saturation was monitored for at least
30 min. At the end of this period subjects were asked to
hyperventilate until they experienced a subjective sen¬
sation of light-headedness, at which point they returned to
their usual breathing pattern. Note was taken of the time
of onset and termination of hyperventilation. The sensors
were then resited so that each was placed contralateral to its
original position and the above procedure was repeated.
Although the Somanetics sensor is not designed to be
reused, its adhesive properties were adequate for this single
change in position. Data from both oximeters were logged
continuously to a personal computer interfaced to the
monitors at intervals of 15 s.
Comparisons were made of the ability of the monitors
to provide stable readings of rso2 and of their relative
performance in male and female subjects. Mean rso2
values were calculated for each oximeter for the first
30 min of recording. These values were used in a
method comparison analysis [6] to assess the agreement
(a) between oximeters running simultaneously and (b)
within oximeters sequentially left and right. The mean
change in signal observed during hyperventilation was
analysed using the same methods in order to compare
size and direction of the change in rso2 reported. When
the bias between paired oximeter readings was not con¬
stant over the range of values observed, a correlated
regression model was fitted to the bias using the general¬
ised estimating equation (GEE) approach [7]. All analysis
was carried out using S-plus for Windows 3.2, and the
GEE models fitted using add-on functions supplied by
V. Carey and A. McDermott of Harvard Medical School.
Results
Ten of the 18 volunteers participating in the study
were successfully monitored for the full hour (eight
women, two men. mean age 23 years). In one subject
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Table 1 Ability ofCritikon 2020 to successfully monitor cerebral
oxygen saturation.
Subjects
Critikon successful in monitoring?
Yes No Total
Female 8 0 8
Male 2 8 10
Total 10 8 18
both systems recorded adequately for the first 30 nun
but, on relocation of the sensors, the Critikon failed to
continue monitoring acceptable values. In two cases the
Invos performed well, while the Critikon reported a poor
or absent signal; in another two, neither oximeter was able
to provide reliable readings. Three subjects were aban¬
doned on the basis of Critikon signal problems without
assessing the reliability of the Invos measurement. Thus,
failure to obtain a stable reading occurred in eight out of
18 attempts using the Critikon and in two out of 15 using
the Invos. The latter was found to work in two instances
where the former failed but there were no comparable
cases where the Critikon monitored successfully while the
Invos did not. In all cases where one or both oximeters
were unable to record adequately, the subjects were male;
the Critikon showed a significantly higher failure rate
in the male participants (Table 1, Fisher's exact test,
p = 0.0011).
A total of 10.5 h of data were recorded simultaneously
by both monitors from 11 subjects (Table 2). A plot of the
difference between the oximeter readings against their
average value (Fig. 1) shows a clear trend for the bias to
change with the underlying value of rso2. For rso2 values
in the lower range the Critikon tends to read 5—10%
higher than the Invos, with the reverse being true at high
saturations. To explore possible causes of this phenomenon
a GEE regression model was fitted, which takes account of
the fact that there were two correlated measurements from
each subject. There was no significant effect upon the bias
of either the order of measurement (first 30 min vs. second
Table 2 A comparison of baseline readings.




Standard deviation 2.1 6.1
* Regional cerebral oxygen saturation.
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Figure 1 Differences between the regional cerebral oxygen saturation (rso2) shown by the Cririkon and Invos monitors, plotted against
their average, tor each 30-min period. The letters A-K represent individual subjects.
30min, p = 0.657) or the location of the oximeters
(Critikon left vs. Critikon right, p = 0.436), but there
was a highly significant relationship between the bias and
the average rso2 (slope = —1.22, p < 0.0001). The fitted
regression line is plotted on Fig. 1 and shows that, from the
point of agreement at an rso2 of approximately 69%, for
each percentage point decrease in rso2, the difference
between the monitors would be predicted to increase by
1.22%. The estimated correlation between differences
observed within the same subject was 0.133.
For the within-monitor comparisons, there was no
apparent relationship between the side-to-side differences
and the average value. The observed bias (right — left)
for each monitor was not significantly different from zero
(Critikon, mean = —0.01, p = 0.985; Invos, mean =
2.08, p = 0.113). The Invos, however, did show signifi¬
cantly more variability (F-test for homogeneity
p = 0.0124) and this is reflected in the limits ofagreement,
which are —3.3% to 3.3% for the Critikon and —6.1% to
10.2% for the Invos (Fig. 2).
For the hyperventilation phase of the experiment
observed changes in rso2 ranged from —4.0% to 1.2%
for the Critikon and from —9% to 1% for the Invos. Once
again the size of the disagreement between monitors
was related to the size of the change; the larger the
average decrease in rso2 the larger the difference
between monitors. A GEE regression model estimates
the point of agreement at approximately —1% and predicts
that for every 1% drop in rso2 the difference between the
monitors (Critikon — Invos) will increase by 1.5%
(p < 0.0001).
Discussion
Much controversy surrounds the validity of rso2 measure¬
ments obtained by reflectance cerebral near-infrared spec¬
troscopy [8-10]. The original technique requires
transillumination of the neonatal skull, where determi¬
nation of the optical pathlength (the distance travelled by
the photons from emitter to detector) is easily measured.
This is not the case in adults, where the use of reflectance
spectroscopy means that optical pathlength can only be
estimated using complex modelling techniques (e.g. the
Monte Carlo method [11]). The use of a coherent light
source, with greater penetrance and less scatter, has
theoretical advantages when using these models. In this
manner the Critikon 2020, using laser optodes, should
be superior to the Invos 3100, which uses a diffuse light
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Figure 2 Differences between the average regional cerebral oxygen saturation (rso2) shown by each monitor for each 30-min
monitoring period, plotted against their average for the total 60min ( bias; — • — • limits of agreement).
source. A further and important difference between the
two monitors is the choice of algorithm for quantification
of rso2. The Critikon uses simultaneous solution of matrix
equations of all chromophore absorption, whereas the
Invos relies upon a questionable assumption of the com-
partmentalisation of the cerebral vascular bed.
Our original intention was to conduct this study on
ventilated patients in the Intensive Care Unit and was
motivated by several factors. Firstly, this technology has
been developed for clinical settings such as intensive care
where cerebral oxygenation is likely to become com¬
promised and should therefore be assessed within that
environment. Secondly, working with this population
would have allowed a much longer total monitoring
time per.subject and minimised the effect of movement
artefacts, shown to influence NIRS signals [12], Finally,
we intended to manipulate arterial oxygen saturation and
partial pressure of carbon dioxide and correlate these
changes with any alteration in rso2 reported by each of
the oximeters. The insurmountable signal problems
experienced with the Critikon instrument forced a radical
revision of the original protocol. It failed to register an
& 1997 Blackweil Science Ltd
adequate signal from any of the four ITU patients to whom
it was applied whilst simultaneous monitoring by the Invos
instrument appeared to be consistent and stable. The
decision to use healthy subjects was based on the finding
that acceptable Critikon readings were only obtainable
from this group.
Our results in volunteers demonstrate a higher failure
rate with the Critikon than with the Invos. Although the
Invos performed poorly in two cases, the Critikon also
failed to record. It can be concluded that the Invos system
is the more likely of the two to provide a recording that is
continuous and stable. The incessant and frustrating 'poor
signal' alarm that we experienced with the Critikon is
totally unacceptable in a clinical environment.
We observed a strong positive association between fail¬
ure of the Critikon monitor and male sex. Anatomical
features of the head, for example skull thickness and mass
of overlying muscle, are known to vary considerably
between individuals and between different cranial regions
[13. 14], which would support the hypothesis that the
extent of infrared light scattering also shows inter- and
intrasubject variability [15]. Adult women tend to have
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smaller, lighter and thinner skulls than men [14]; the exist¬
ence of special features, including the prominence of the
supraorbital ridges and the contours of the forehead, which
can be used to distinguish between male and female crania
[16] is ofparticular relevance to the present findings. Further
support for the observed sex difference is drawn from the
suggestion that the amount of light collected by NIRS at a
fixed space is greater for women than for men [15].
Assuming that a similar rso2 can be expected in equiva¬
lent areas of the two hemispheres in a healthy person, the
side-to-side comparisons show that the Critikon monitor,
despite the high failure rate, does appear to have signifi¬
cantly less inherent variability than the Invos. However,
the dependence of the disagreement between the monitors
upon the underlying value of rso2 suggests that either one
or both of these machines is not giving an accurate value
for regional cerebral oxygen saturation. A difference of
up to 10% for values of rso2 in the range given by healthy
volunteers does not bode well for clinical application of
these monitors.
The values of rso2 from both monitors decreased during
hyperventilation, as was expected, since systemic hypo-
capnia is known to result in cerebral vasoconstriction.
Again the disagreement between the monitors varied with
the average value, providing further evidence of the
uncertainty of these values of rS02. However, without
objective assessment of the change in arterial blood gas
tensions it is difficult to analyse the significance of these
changes. In the majority of cases the Invos showed the
greater mean decrease in rso2, a finding that differs from a
previous report in which it failed to respond to an episode
of hypercapnia [9], That study produced more detailed
and direct measurements and it therefore seems plausible
that the limitations of the present study design may be
responsible for any discrepancies.
It is generally accepted that reflectance spectroscopy
will become useful as a monitor of tissue oxygenation,
and signal changes attributable to variations in cerebral
oxygenation have indeed been demonstrated [12, 17, 18].
However, further development is required before this
technique becomes commonly applied in the intensive
care situation. The different algorithms used by the
two systems assessed in the present study may explain
some of the lack of agreement between them. We strongly
suspect that deficiencies in sensor design may explain the
unacceptably high failure rate in monitoring attributable
to the Critikon instrument.
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